MedWorm.com provides a medical RSS filtering service. Over 6000 RSS medical sources are combined and output via different filters. This feed contains the latest items from the 'Gynecologic Oncology' source. Thu, 11 Mar 2010 13:53:37 +0100 http://www.medworm.com/index.php?rid=3347790&cid=s_35590_6_f&fid=35590&url=http%3A%2F%2Fwww.ncbi.nlm.nih.gov%2Fentrez%2Fquery.fcgi%3Ftmpl%3DNoSidebarfile%26db%3DPubMed%26cmd%3DRetrieve%26list_uids%3D20207398%26dopt%3DAbstract CONCLUSIONS: Future studies, such as the Cancer Genome Atlas Project, involving a large number of ovarian tumors and combining various high-throughput genetic technologies with sophisticated integrative bioinformatic analyses, will be required and are expected to fine-map the full genetic spectrum of ovarian cancer. It is hoped, however, that once the molecular genetic basis of ovarian cancer is understood, this will lead to better and personalized treatments for ovarian cancer. PMID: 20207398 [PubMed - as supplied by publisher] (Source: Gynecologic Oncology) Gynecologic Oncology journals http://www.medworm.com/rss/comments.php?id=3347790 Sat, 06 Mar 2010 00:00:00 +0100 3347790 http://www.medworm.com/index.php?rid=3347789&cid=s_35590_6_f&fid=35590&url=http%3A%2F%2Fwww.ncbi.nlm.nih.gov%2Fentrez%2Fquery.fcgi%3Ftmpl%3DNoSidebarfile%26db%3DPubMed%26cmd%3DRetrieve%26list_uids%3D20211485%26dopt%3DAbstract CONCLUSIONS: Hypermethylation of CIDEA, HAAO and RXFP3 promoter regions appears to be a frequent event in endometrial carcinomas. Hypermethylation at these loci is strongly associated with microsatellite instability status. Moreover, HAAO methylation predicts disease-free survival in this cohort of patients with endometrioid endometrial cancer. PMID: 20211485 [PubMed - as supplied by publisher] (Source: Gynecologic Oncology) Gynecologic Oncology journals http://www.medworm.com/rss/comments.php?id=3347789 Sat, 06 Mar 2010 00:00:00 +0100 3347789 http://www.medworm.com/index.php?rid=3347791&cid=s_35590_6_f&fid=35590&url=http%3A%2F%2Fwww.ncbi.nlm.nih.gov%2Fentrez%2Fquery.fcgi%3Ftmpl%3DNoSidebarfile%26db%3DPubMed%26cmd%3DRetrieve%26list_uids%3D20207397%26dopt%3DAbstract CONCLUSION: Asian American variant of HPV16, HPV18 and HPV45 are preferentially associated with cervical adenocarcinoma as compared to squamous cell carcinoma. PMID: 20207397 [PubMed - as supplied by publisher] (Source: Gynecologic Oncology) Gynecologic Oncology journals http://www.medworm.com/rss/comments.php?id=3347791 Fri, 05 Mar 2010 00:00:00 +0100 3347791 http://www.medworm.com/index.php?rid=3347792&cid=s_35590_6_f&fid=35590&url=http%3A%2F%2Fwww.ncbi.nlm.nih.gov%2Fentrez%2Fquery.fcgi%3Ftmpl%3DNoSidebarfile%26db%3DPubMed%26cmd%3DRetrieve%26list_uids%3D20206982%26dopt%3DAbstract CONCLUSIONS: Reliable determination of HPV status is crucially dependent on the amount of input genomic DNA. PMID: 20206982 [PubMed - as supplied by publisher] (Source: Gynecologic Oncology) Gynecologic Oncology journals http://www.medworm.com/rss/comments.php?id=3347792 Thu, 04 Mar 2010 00:00:00 +0100 3347792 http://www.medworm.com/index.php?rid=3338595&cid=s_35590_6_f&fid=35590&url=http%3A%2F%2Fwww.ncbi.nlm.nih.gov%2Fentrez%2Fquery.fcgi%3Ftmpl%3DNoSidebarfile%26db%3DPubMed%26cmd%3DRetrieve%26list_uids%3D20199802%26dopt%3DAbstract CONCLUSION: Although a rare event, endometrial cancer can metastasize to the bone. If a bone lesion is identified, treatment using a multimodality approach is reasonable, especially if found as an isolated recurrence. PMID: 20199802 [PubMed - as supplied by publisher] (Source: Gynecologic Oncology) Gynecologic Oncology journals http://www.medworm.com/rss/comments.php?id=3338595 Mon, 01 Mar 2010 00:00:00 +0100 3338595 http://www.medworm.com/index.php?rid=3338594&cid=s_35590_6_f&fid=35590&url=http%3A%2F%2Fwww.ncbi.nlm.nih.gov%2Fentrez%2Fquery.fcgi%3Ftmpl%3DNoSidebarfile%26db%3DPubMed%26cmd%3DRetrieve%26list_uids%3D20199803%26dopt%3DAbstract CONCLUSIONS.: Genetic variants in CYP11A1 may influence endometrial cancer risk or may be markers for causal variants elsewhere. Polymorphisms in StAR are not associated with endometrial cancer risk, but further research is needed. PMID: 20199803 [PubMed - as supplied by publisher] (Source: Gynecologic Oncology) Gynecologic Oncology journals http://www.medworm.com/rss/comments.php?id=3338594 Mon, 01 Mar 2010 00:00:00 +0100 3338594 http://www.medworm.com/index.php?rid=3338593&cid=s_35590_6_f&fid=35590&url=http%3A%2F%2Fwww.ncbi.nlm.nih.gov%2Fentrez%2Fquery.fcgi%3Ftmpl%3DNoSidebarfile%26db%3DPubMed%26cmd%3DRetrieve%26list_uids%3D20199804%26dopt%3DAbstract CONCLUSION.: This study contributes to the knowledge of regional prevalence of HPV types in the whole spectrum of disease, which can be useful in the application of prophylactic vaccines against HPV and in the viral screening methods. PMID: 20199804 [PubMed - as supplied by publisher] (Source: Gynecologic Oncology) Gynecologic Oncology journals http://www.medworm.com/rss/comments.php?id=3338593 Mon, 01 Mar 2010 00:00:00 +0100 3338593 http://www.medworm.com/index.php?rid=3331867&cid=s_35590_6_f&fid=35590&url=http%3A%2F%2Fwww.ncbi.nlm.nih.gov%2Fentrez%2Fquery.fcgi%3Ftmpl%3DNoSidebarfile%26db%3DPubMed%26cmd%3DRetrieve%26list_uids%3D20171349%26dopt%3DAbstract Authors: PMID: 20171349 [PubMed - in process] (Source: Gynecologic Oncology) Gynecologic Oncology journals http://www.medworm.com/rss/comments.php?id=3331867 Mon, 01 Mar 2010 00:00:00 +0100 3331867 http://www.medworm.com/index.php?rid=3280486&cid=s_35590_6_f&fid=35590&url=http%3A%2F%2Fwww.ncbi.nlm.nih.gov%2Fentrez%2Fquery.fcgi%3Ftmpl%3DNoSidebarfile%26db%3DPubMed%26cmd%3DRetrieve%26list_uids%3D20152512%26dopt%3DAbstract Authors: Trimble EL, Denicoff AM, Abrams JS PMID: 20152512 [PubMed - in process] (Source: Gynecologic Oncology) Gynecologic Oncology journals http://www.medworm.com/rss/comments.php?id=3280486 Wed, 17 Feb 2010 23:39:22 +0100 3280486 http://www.medworm.com/index.php?rid=3280483&cid=s_35590_6_f&fid=35590&url=http%3A%2F%2Fwww.ncbi.nlm.nih.gov%2Fentrez%2Fquery.fcgi%3Ftmpl%3DNoSidebarfile%26db%3DPubMed%26cmd%3DRetrieve%26list_uids%3D20153882%26dopt%3DAbstract Authors: Paradisi R, Fabbri R, Magnani V, Battaglia C, Venturoli S PMID: 20153882 [PubMed - as supplied by publisher] (Source: Gynecologic Oncology) Gynecologic Oncology journals http://www.medworm.com/rss/comments.php?id=3280483 Fri, 12 Feb 2010 00:00:00 +0100 3280483 http://www.medworm.com/index.php?rid=3280482&cid=s_35590_6_f&fid=35590&url=http%3A%2F%2Fwww.ncbi.nlm.nih.gov%2Fentrez%2Fquery.fcgi%3Ftmpl%3DNoSidebarfile%26db%3DPubMed%26cmd%3DRetrieve%26list_uids%3D20153883%26dopt%3DAbstract CONCLUSIONS.: The removal of greater than 10 lymph nodes was associated with a significant improvement in DSS in patients with stage III vulvar carcinoma. This improvement in survival may be due to removal of micrometastatic disease in the inguinal lymph nodes. These data suggest that a thorough inguinal-femoral lymph node dissection should be performed in patients with advanced-stage node-negative vulvar carcinoma. PMID: 20153883 [PubMed - as supplied by publisher] (Source: Gynecologic Oncology) Gynecologic Oncology journals http://www.medworm.com/rss/comments.php?id=3280482 Fri, 12 Feb 2010 00:00:00 +0100 3280482 http://www.medworm.com/index.php?rid=3280481&cid=s_35590_6_f&fid=35590&url=http%3A%2F%2Fwww.ncbi.nlm.nih.gov%2Fentrez%2Fquery.fcgi%3Ftmpl%3DNoSidebarfile%26db%3DPubMed%26cmd%3DRetrieve%26list_uids%3D20153884%26dopt%3DAbstract CONCLUSIONS: These findings show that 10% flaxseed supplementation for 1 year in the laying hen results in a significant reduction in the severity of ovarian cancer, but no change in the incidence of the disease. Hens fed flaxseed had overall better health and reduced mortality. These findings may provide the basis for a clinical trial that evaluates the efficacy of flaxseed as a chemosuppressant of ovarian cancer in women. PMID: 20153884 [PubMed - as supplied by publisher] (Source: Gynecologic Oncology) Gynecologic Oncology journals http://www.medworm.com/rss/comments.php?id=3280481 Fri, 12 Feb 2010 00:00:00 +0100 3280481 http://www.medworm.com/index.php?rid=3280480&cid=s_35590_6_f&fid=35590&url=http%3A%2F%2Fwww.ncbi.nlm.nih.gov%2Fentrez%2Fquery.fcgi%3Ftmpl%3DNoSidebarfile%26db%3DPubMed%26cmd%3DRetrieve%26list_uids%3D20153885%26dopt%3DAbstract CONCLUSIONS: Subgroups of patients with non-endometrioid endometrial cancer and defective MMR may have improved survival after adjuvant radiotherapy. Patients with advanced stage endometrial cancer and defects in mismatch repair may receive less benefit from adjuvant chemotherapy. PMID: 20153885 [PubMed - as supplied by publisher] (Source: Gynecologic Oncology) Gynecologic Oncology journals http://www.medworm.com/rss/comments.php?id=3280480 Fri, 12 Feb 2010 00:00:00 +0100 3280480 http://www.medworm.com/index.php?rid=3280479&cid=s_35590_6_f&fid=35590&url=http%3A%2F%2Fwww.ncbi.nlm.nih.gov%2Fentrez%2Fquery.fcgi%3Ftmpl%3DNoSidebarfile%26db%3DPubMed%26cmd%3DRetrieve%26list_uids%3D20153886%26dopt%3DAbstract CONCLUSIONS.: RRH is safe and feasible and has been shown to be associated with improved operative measures. This study shows that at 3 years, RRH appears to have PFS and OS equivalent to that of traditional laparotomy. Longer follow-up is needed, but early data are supportive of at least equivalent oncologic outcomes compared with other surgical modalities. PMID: 20153886 [PubMed - as supplied by publisher] (Source: Gynecologic Oncology) Gynecologic Oncology journals http://www.medworm.com/rss/comments.php?id=3280479 Fri, 12 Feb 2010 00:00:00 +0100 3280479 http://www.medworm.com/index.php?rid=3280485&cid=s_35590_6_f&fid=35590&url=http%3A%2F%2Fwww.ncbi.nlm.nih.gov%2Fentrez%2Fquery.fcgi%3Ftmpl%3DNoSidebarfile%26db%3DPubMed%26cmd%3DRetrieve%26list_uids%3D20153027%26dopt%3DAbstract CONCLUSIONS: In patients with platinum-sensitive EOC, detection of asymptomatic recurrences by routine surveillance testing was associated with a high likelihood of optimal SCRS in operative candidates and extended overall survival. PMID: 20153027 [PubMed - as supplied by publisher] (Source: Gynecologic Oncology) Gynecologic Oncology journals http://www.medworm.com/rss/comments.php?id=3280485 Wed, 10 Feb 2010 00:00:00 +0100 3280485 http://www.medworm.com/index.php?rid=3280484&cid=s_35590_6_f&fid=35590&url=http%3A%2F%2Fwww.ncbi.nlm.nih.gov%2Fentrez%2Fquery.fcgi%3Ftmpl%3DNoSidebarfile%26db%3DPubMed%26cmd%3DRetrieve%26list_uids%3D20153028%26dopt%3DAbstract Authors: Sert MB PMID: 20153028 [PubMed - as supplied by publisher] (Source: Gynecologic Oncology) Gynecologic Oncology journals http://www.medworm.com/rss/comments.php?id=3280484 Wed, 10 Feb 2010 00:00:00 +0100 3280484 http://www.medworm.com/index.php?rid=3270195&cid=s_35590_6_f&fid=35590&url=http%3A%2F%2Fwww.ncbi.nlm.nih.gov%2Fentrez%2Fquery.fcgi%3Ftmpl%3DNoSidebarfile%26db%3DPubMed%26cmd%3DRetrieve%26list_uids%3D20149423%26dopt%3DAbstract Authors: Markman M PMID: 20149423 [PubMed - as supplied by publisher] (Source: Gynecologic Oncology) Gynecologic Oncology journals http://www.medworm.com/rss/comments.php?id=3270195 Mon, 08 Feb 2010 00:00:00 +0100 3270195 http://www.medworm.com/index.php?rid=3263533&cid=s_35590_6_f&fid=35590&url=http%3A%2F%2Fwww.ncbi.nlm.nih.gov%2Fentrez%2Fquery.fcgi%3Ftmpl%3DNoSidebarfile%26db%3DPubMed%26cmd%3DRetrieve%26list_uids%3D20144842%26dopt%3DAbstract CONCLUSION: Further knowledge of the mechanisms involved is needed to develop better strategies and improve the clinical applicability of immunotherapy. Effective immunotherapy must combine immune-activating strategies with elimination of immune-suppressing mechanisms. We believe that tilting the balance from an immune-suppressive to an immune-active environment may have an enormous impact on the disease. PMID: 20144842 [PubMed - as supplied by publisher] (Source: Gynecologic Oncology) Gynecologic Oncology journals http://www.medworm.com/rss/comments.php?id=3263533 Sun, 07 Feb 2010 00:00:00 +0100 3263533 http://www.medworm.com/index.php?rid=3263532&cid=s_35590_6_f&fid=35590&url=http%3A%2F%2Fwww.ncbi.nlm.nih.gov%2Fentrez%2Fquery.fcgi%3Ftmpl%3DNoSidebarfile%26db%3DPubMed%26cmd%3DRetrieve%26list_uids%3D20144843%26dopt%3DAbstract Authors: Kohorn EI PMID: 20144843 [PubMed - as supplied by publisher] (Source: Gynecologic Oncology) Gynecologic Oncology journals http://www.medworm.com/rss/comments.php?id=3263532 Sun, 07 Feb 2010 00:00:00 +0100 3263532 http://www.medworm.com/index.php?rid=3263535&cid=s_35590_6_f&fid=35590&url=http%3A%2F%2Fwww.ncbi.nlm.nih.gov%2Fentrez%2Fquery.fcgi%3Ftmpl%3DNoSidebarfile%26db%3DPubMed%26cmd%3DRetrieve%26list_uids%3D20144470%26dopt%3DAbstract Authors: Lou E, Hensley ML, Lassman A, Aghajanian C PMID: 20144470 [PubMed - as supplied by publisher] (Source: Gynecologic Oncology) Gynecologic Oncology journals http://www.medworm.com/rss/comments.php?id=3263535 Sat, 06 Feb 2010 00:00:00 +0100 3263535 http://www.medworm.com/index.php?rid=3263534&cid=s_35590_6_f&fid=35590&url=http%3A%2F%2Fwww.ncbi.nlm.nih.gov%2Fentrez%2Fquery.fcgi%3Ftmpl%3DNoSidebarfile%26db%3DPubMed%26cmd%3DRetrieve%26list_uids%3D20144471%26dopt%3DAbstract CONCLUSION: Robotic-assisted surgery is an acceptable alternative to laparoscopy for minimally invasive staging of endometrial cancer. In addition to the improved ease of operation, visualization, and range of motion of the robotic instruments, robotic surgery results in a lower mean blood loss, although longer operative time. More data are needed to determine if the rates of urinary tract injuries and other surgical complications can be reduced with the use of robotic surgery. PMID: 20144471 [PubMed - as supplied by publisher] (Source: Gynecologic Oncology) Gynecologic Oncology journals http://www.medworm.com/rss/comments.php?id=3263534 Sat, 06 Feb 2010 00:00:00 +0100 3263534 http://www.medworm.com/index.php?rid=3263536&cid=s_35590_6_f&fid=35590&url=http%3A%2F%2Fwww.ncbi.nlm.nih.gov%2Fentrez%2Fquery.fcgi%3Ftmpl%3DNoSidebarfile%26db%3DPubMed%26cmd%3DRetrieve%26list_uids%3D20138657%26dopt%3DAbstract CONCLUSION: The rate of 31% HPV-positive VSCC in Sweden is similar to other reports. As far as we know, HPV in SN in VSCC never been investigated previously. The differences in age, tumor size, prevalence of HPV in SN and survival of patients with HPV-positive and negative VSCC support the assumption that VSCC develops through two different pathways, with better survival for patients with HPV-positive tumors. Presence of HPV DNA in SN was related to metastatic disease but did not affect survival in this study. PMID: 20138657 [PubMed - as supplied by publisher] (Source: Gynecologic Oncology) Gynecologic Oncology journals http://www.medworm.com/rss/comments.php?id=3263536 Fri, 05 Feb 2010 00:00:00 +0100 3263536 http://www.medworm.com/index.php?rid=3263539&cid=s_35590_6_f&fid=35590&url=http%3A%2F%2Fwww.ncbi.nlm.nih.gov%2Fentrez%2Fquery.fcgi%3Ftmpl%3DNoSidebarfile%26db%3DPubMed%26cmd%3DRetrieve%26list_uids%3D20138345%26dopt%3DAbstract Authors: Giuliano AR, Anic G, Nyitray AG It is currently recognized that besides the significant impact of human papillomavirus (HPV) infection in females, HPV causes substantial disease in men as well. Genital warts are a common manifestation of male infection with HPV. Genital warts are highly infectious and approximately 65% of people who have sex with an infected partner will develop warts themselves. More than 90% of genital warts are caused by non-oncogenic HPV types 6 and 11. In addition, recurrent respiratory papillomatosis is a rare disease most often associated with HPV types 6 and 11. Several cancers of the anogenital tract and upper aero-digestive tract, and their precursor lesions in men are now understood to be caused by infection with sexually transmitted HPV. For exampl... Gynecologic Oncology journals http://www.medworm.com/rss/comments.php?id=3263539 Thu, 04 Feb 2010 00:00:00 +0100 3263539 http://www.medworm.com/index.php?rid=3263538&cid=s_35590_6_f&fid=35590&url=http%3A%2F%2Fwww.ncbi.nlm.nih.gov%2Fentrez%2Fquery.fcgi%3Ftmpl%3DNoSidebarfile%26db%3DPubMed%26cmd%3DRetrieve%26list_uids%3D20138346%26dopt%3DAbstract CONCLUSIONS: For clinically localized endometrial cancer, TLH/BSO/LND can functionally duplicate operative time equivalent to "open" procedures, while improving nodal yield, and minimizing influence of BMI on conversion to laparotomy and case selection. PMID: 20138346 [PubMed - as supplied by publisher] (Source: Gynecologic Oncology) Gynecologic Oncology journals http://www.medworm.com/rss/comments.php?id=3263538 Thu, 04 Feb 2010 00:00:00 +0100 3263538 http://www.medworm.com/index.php?rid=3263537&cid=s_35590_6_f&fid=35590&url=http%3A%2F%2Fwww.ncbi.nlm.nih.gov%2Fentrez%2Fquery.fcgi%3Ftmpl%3DNoSidebarfile%26db%3DPubMed%26cmd%3DRetrieve%26list_uids%3D20138347%26dopt%3DAbstract Authors: Garland SM Sexually transmitted human papillomavirus (HPV) infection is very common in men and women. Oncogenic HPV is strongly associated with cancers and high-grade dysplasias of the anogenital tract, including the anus, penis, and also a proportion of oropharyngeal cancers. In reducing male disease burden, some consider screening and treatment for high-grade anal dysplasia (AIN) to prevent anal cancer in high-risk populations. Such strategies have wide implications for the workforce, and require more evidence for the optimal management of AIN. Male sexual behavior, with consequent HPV infection and disease contribute to considerable disease burden in females. Hence, inclusion of males in prophylactic HPV vaccination programs should prevent HPV-related disease in males as we... Gynecologic Oncology journals http://www.medworm.com/rss/comments.php?id=3263537 Thu, 04 Feb 2010 00:00:00 +0100 3263537 http://www.medworm.com/index.php?rid=3247146&cid=s_35590_6_f&fid=35590&url=http%3A%2F%2Fwww.ncbi.nlm.nih.gov%2Fentrez%2Fquery.fcgi%3Ftmpl%3DNoSidebarfile%26db%3DPubMed%26cmd%3DRetrieve%26list_uids%3D20132968%26dopt%3DAbstract CONCLUSION AND RECOMMENDATIONS: Several pathways identified have previously been shown to be associated with therapy resistance: these include 'oxidative stress response mediated by Nrf2,' 'TP53 signaling' and 'TGFbeta signaling.' The role of TGFbeta signaling and related miRNAs identified in the network analysis in epithelial-to-mesenchymal transition (EMT) and stemness as well as the possible relation with platin-based chemotherapy resistance are further discussed in detail. We propose that future international cooperation should aim at a uniform pooled analysis of the wealth of ovarian cancer array data already available. This will enhance the power of each separate ovarian cancer study and can lead to promising results. PMID: 20132968 [PubMed - as supplied by publisher] (Source: Gy... Gynecologic Oncology journals http://www.medworm.com/rss/comments.php?id=3247146 Wed, 03 Feb 2010 00:00:00 +0100 3247146 http://www.medworm.com/index.php?rid=3247149&cid=s_35590_6_f&fid=35590&url=http%3A%2F%2Fwww.ncbi.nlm.nih.gov%2Fentrez%2Fquery.fcgi%3Ftmpl%3DNoSidebarfile%26db%3DPubMed%26cmd%3DRetrieve%26list_uids%3D20129652%26dopt%3DAbstract Authors: Cuzick J Worldwide, there are several approaches for the prevention of cervical cancer, and in the near future it is likely that human papillomavirus (HPV) vaccination and HPV-based screening will be complementary strategies. In the US, professional guidelines on HPV screening recommend a co-testing approach utilizing HPV DNA testing and cytology in women aged >/=30 years. However, a growing body of evidence indicates that HPV testing is more sensitive than cytology, suggesting that HPV DNA testing may be more useful as the sole primary screening modality, especially for newly implemented programs. HPV vaccination programs targeted at young girls have been widely implemented in several affluent countries, and currently available data confirm the long-term efficacy of the VL... Gynecologic Oncology journals http://www.medworm.com/rss/comments.php?id=3247149 Mon, 01 Feb 2010 00:00:00 +0100 3247149 http://www.medworm.com/index.php?rid=3247148&cid=s_35590_6_f&fid=35590&url=http%3A%2F%2Fwww.ncbi.nlm.nih.gov%2Fentrez%2Fquery.fcgi%3Ftmpl%3DNoSidebarfile%26db%3DPubMed%26cmd%3DRetrieve%26list_uids%3D20129653%26dopt%3DAbstract Authors: Zimet GD, Rosenthal SL The quadrivalent vaccine has been shown to be safe and efficacious against HPV infection in men. It is expected, though, that male vaccination rates will remain low. Therefore this literature review examines the attitudes of parents, young men, and HCPs toward HPV vaccination and other sexually transmitted infections (STI). It appears that parents are interested in vaccinating their sons against HPV and other (STI). In addition, adolescent and adult males are interested in receipt of HPV vaccine and other vaccines for prevention of STI. Health care providers have a general preference for vaccinating females, but they indicate a willingness to recommend HPV vaccine for their male patients. This is important given the "permissive" recommendation for male H... Gynecologic Oncology journals http://www.medworm.com/rss/comments.php?id=3247148 Mon, 01 Feb 2010 00:00:00 +0100 3247148 http://www.medworm.com/index.php?rid=3247147&cid=s_35590_6_f&fid=35590&url=http%3A%2F%2Fwww.ncbi.nlm.nih.gov%2Fentrez%2Fquery.fcgi%3Ftmpl%3DNoSidebarfile%26db%3DPubMed%26cmd%3DRetrieve%26list_uids%3D20129654%26dopt%3DAbstract Authors: Kane MA Development of safe and effective vaccines against human papillomavirus (HPV)-the second vaccine against a major human cancer-is one of the most important medical and public health achievements of this century. As with all new vaccines, HPV is currently expensive and this cost precludes its use in the developing world, which has the greatest burden of disease from HPV-related cancers. Hepatitis B (HB) virus vaccine, which prevents chronic HB infection and related cirrhosis and liver cancer, has been successfully introduced as a routine vaccine for children in 89% of countries, including the poorest. The success of this vaccine provides a model for the introduction of HPV vaccine and control of cervical and other HPV-related cancers and genital warts. Lessons learned fr... Gynecologic Oncology journals http://www.medworm.com/rss/comments.php?id=3247147 Mon, 01 Feb 2010 00:00:00 +0100 3247147 http://www.medworm.com/index.php?rid=3225174&cid=s_35590_6_f&fid=35590&url=http%3A%2F%2Fwww.ncbi.nlm.nih.gov%2Fentrez%2Fquery.fcgi%3Ftmpl%3DNoSidebarfile%26db%3DPubMed%26cmd%3DRetrieve%26list_uids%3D20109724%26dopt%3DAbstract Authors: Sood AK, Coleman RL PMID: 20109724 [PubMed - in process] (Source: Gynecologic Oncology) Gynecologic Oncology journals http://www.medworm.com/rss/comments.php?id=3225174 Mon, 01 Feb 2010 00:00:00 +0100 3225174 http://www.medworm.com/index.php?rid=3225173&cid=s_35590_6_f&fid=35590&url=http%3A%2F%2Fwww.ncbi.nlm.nih.gov%2Fentrez%2Fquery.fcgi%3Ftmpl%3DNoSidebarfile%26db%3DPubMed%26cmd%3DRetrieve%26list_uids%3D20109725%26dopt%3DAbstract CONCLUSION: Gefitinib, administered in combination with paclitaxel and carboplatin, provides a good clinical response but associated with an increased risk of hematologic disorders. PMID: 20109725 [PubMed - as supplied by publisher] (Source: Gynecologic Oncology) Gynecologic Oncology journals http://www.medworm.com/rss/comments.php?id=3225173 Mon, 01 Feb 2010 00:00:00 +0100 3225173 http://www.medworm.com/index.php?rid=3225172&cid=s_35590_6_f&fid=35590&url=http%3A%2F%2Fwww.ncbi.nlm.nih.gov%2Fentrez%2Fquery.fcgi%3Ftmpl%3DNoSidebarfile%26db%3DPubMed%26cmd%3DRetrieve%26list_uids%3D20109726%26dopt%3DAbstract Authors: Harry VN The use of novel imaging techniques that have the ability to evaluate tumour biology and function shows a great deal of promise in providing early surrogate biomarkers of response to therapy which may allow for individualised or patient-specific regimes. This would have considerable clinical benefit in allowing for a treatment regimen tailored accordingly to meet the expected response, thereby reducing morbidity. Several of these imaging modalities such as dynamic contrast-enhanced MRI (DCE-MRI), diffusion-weighted MRI (DW-MRI), MR spectroscopy (MRS) and fluorine-18 fluorodeoxyglucose positron emission tomography (FDG-PET) are now being introduced into the field of gynaecological oncology, with the majority of work being performed on cervical tumours. This review exam... Gynecologic Oncology journals http://www.medworm.com/rss/comments.php?id=3225172 Mon, 01 Feb 2010 00:00:00 +0100 3225172 http://www.medworm.com/index.php?rid=3225171&cid=s_35590_6_f&fid=35590&url=http%3A%2F%2Fwww.ncbi.nlm.nih.gov%2Fentrez%2Fquery.fcgi%3Ftmpl%3DNoSidebarfile%26db%3DPubMed%26cmd%3DRetrieve%26list_uids%3D20109727%26dopt%3DAbstract CONCLUSIONS: Since optimal treatment of uterine serous carcinoma remains unknown, novel therapeutic approaches need to be actively pursued. The molecular targets discussed warrant further investigation and suggest a potential role for therapeutic agents targeting HER-2 and EGFR, as well as downstream targets such as the PI3K-AKT-mTOR pathway in the treatment of uterine serous carcinoma. PMID: 20109727 [PubMed - as supplied by publisher] (Source: Gynecologic Oncology) Gynecologic Oncology journals http://www.medworm.com/rss/comments.php?id=3225171 Mon, 01 Feb 2010 00:00:00 +0100 3225171 http://www.medworm.com/index.php?rid=3225168&cid=s_35590_6_f&fid=35590&url=http%3A%2F%2Fwww.ncbi.nlm.nih.gov%2Fentrez%2Fquery.fcgi%3Ftmpl%3DNoSidebarfile%26db%3DPubMed%26cmd%3DRetrieve%26list_uids%3D20110120%26dopt%3DAbstract Authors: Seamon LG, Fowler JM, Cohn DE PMID: 20110120 [PubMed - as supplied by publisher] (Source: Gynecologic Oncology) Gynecologic Oncology journals http://www.medworm.com/rss/comments.php?id=3225168 Wed, 27 Jan 2010 00:00:00 +0100 3225168 http://www.medworm.com/index.php?rid=3225170&cid=s_35590_6_f&fid=35590&url=http%3A%2F%2Fwww.ncbi.nlm.nih.gov%2Fentrez%2Fquery.fcgi%3Ftmpl%3DNoSidebarfile%26db%3DPubMed%26cmd%3DRetrieve%26list_uids%3D20110118%26dopt%3DAbstract CONCLUSION: The majority of the uterine cornua had a tubal remnant which suggests that RRSO may leave behind residual tubal epithelium. The clinical significance of this tubal remnant is unclear given the current understanding of tubal carcinogenesis. PMID: 20110118 [PubMed - as supplied by publisher] (Source: Gynecologic Oncology) Gynecologic Oncology journals http://www.medworm.com/rss/comments.php?id=3225170 Tue, 26 Jan 2010 00:00:00 +0100 3225170 http://www.medworm.com/index.php?rid=3225169&cid=s_35590_6_f&fid=35590&url=http%3A%2F%2Fwww.ncbi.nlm.nih.gov%2Fentrez%2Fquery.fcgi%3Ftmpl%3DNoSidebarfile%26db%3DPubMed%26cmd%3DRetrieve%26list_uids%3D20110119%26dopt%3DAbstract Authors: Frazer IH PMID: 20110119 [PubMed - as supplied by publisher] (Source: Gynecologic Oncology) Gynecologic Oncology journals http://www.medworm.com/rss/comments.php?id=3225169 Tue, 26 Jan 2010 00:00:00 +0100 3225169 http://www.medworm.com/index.php?rid=3221293&cid=s_35590_6_f&fid=35590&url=http%3A%2F%2Fwww.ncbi.nlm.nih.gov%2Fentrez%2Fquery.fcgi%3Ftmpl%3DNoSidebarfile%26db%3DPubMed%26cmd%3DRetrieve%26list_uids%3D20102778%26dopt%3DAbstract CONCLUSION: The mTOR signaling pathway is activated in cervical carcinomas. Inhibition of mTOR represents a potential therapeutic strategy for cervical cancers. PMID: 20102778 [PubMed - as supplied by publisher] (Source: Gynecologic Oncology) Gynecologic Oncology journals http://www.medworm.com/rss/comments.php?id=3221293 Mon, 25 Jan 2010 00:00:00 +0100 3221293 http://www.medworm.com/index.php?rid=3221292&cid=s_35590_6_f&fid=35590&url=http%3A%2F%2Fwww.ncbi.nlm.nih.gov%2Fentrez%2Fquery.fcgi%3Ftmpl%3DNoSidebarfile%26db%3DPubMed%26cmd%3DRetrieve%26list_uids%3D20106510%26dopt%3DAbstract CONCLUSIONS: Despite the low incidence of FGFR2 mutations in ovarian cancer, the two FGFR2 mutations identified in ovarian tumors (S252W, Y376C) overlap with the oncogenic mutations previously identified in endometrial tumors, suggesting activated FGFR2 may contribute to ovarian cancer pathogenesis in a small subset of ovarian tumors. PMID: 20106510 [PubMed - as supplied by publisher] (Source: Gynecologic Oncology) Gynecologic Oncology journals http://www.medworm.com/rss/comments.php?id=3221292 Mon, 25 Jan 2010 00:00:00 +0100 3221292 http://www.medworm.com/index.php?rid=3221291&cid=s_35590_6_f&fid=35590&url=http%3A%2F%2Fwww.ncbi.nlm.nih.gov%2Fentrez%2Fquery.fcgi%3Ftmpl%3DNoSidebarfile%26db%3DPubMed%26cmd%3DRetrieve%26list_uids%3D20106511%26dopt%3DAbstract CONCLUSIONS: The combination of docetaxel, carboplatin and 5-fluorouracil (TCF) appears to have activity in metastatic cervical carcinoma with acceptable toxicity profile. PMID: 20106511 [PubMed - as supplied by publisher] (Source: Gynecologic Oncology) Gynecologic Oncology journals http://www.medworm.com/rss/comments.php?id=3221291 Mon, 25 Jan 2010 00:00:00 +0100 3221291 http://www.medworm.com/index.php?rid=3221290&cid=s_35590_6_f&fid=35590&url=http%3A%2F%2Fwww.ncbi.nlm.nih.gov%2Fentrez%2Fquery.fcgi%3Ftmpl%3DNoSidebarfile%26db%3DPubMed%26cmd%3DRetrieve%26list_uids%3D20106512%26dopt%3DAbstract CONCLUSIONS: Advanced stage ovarian cancer patients have better survival when treated by gynecologic oncology/gynecology trained surgeons. Data suggest that referral to these specialists may optimize surgical debulking and minimize the creation of a fecal ostomy. PMID: 20106512 [PubMed - as supplied by publisher] (Source: Gynecologic Oncology) Gynecologic Oncology journals http://www.medworm.com/rss/comments.php?id=3221290 Mon, 25 Jan 2010 00:00:00 +0100 3221290 http://www.medworm.com/index.php?rid=3221289&cid=s_35590_6_f&fid=35590&url=http%3A%2F%2Fwww.ncbi.nlm.nih.gov%2Fentrez%2Fquery.fcgi%3Ftmpl%3DNoSidebarfile%26db%3DPubMed%26cmd%3DRetrieve%26list_uids%3D20106513%26dopt%3DAbstract CONCLUSION: High risk women need effective education about cervical cancer prevention, HPV, and HPV vaccination. PMID: 20106513 [PubMed - as supplied by publisher] (Source: Gynecologic Oncology) Gynecologic Oncology journals http://www.medworm.com/rss/comments.php?id=3221289 Mon, 25 Jan 2010 00:00:00 +0100 3221289 http://www.medworm.com/index.php?rid=3205657&cid=s_35590_6_f&fid=35590&url=http%3A%2F%2Fwww.ncbi.nlm.nih.gov%2Fentrez%2Fquery.fcgi%3Ftmpl%3DNoSidebarfile%26db%3DPubMed%26cmd%3DRetrieve%26list_uids%3D20097412%26dopt%3DAbstract CONCLUSION: The long-term outcome of patients with pure ovarian dysgerminoma is excellent. Recurrences occur within 2 years of diagnosis and are treatable. Patients can be treated with fertility-sparing surgery and can expect good reproductive outcomes. PMID: 20097412 [PubMed - as supplied by publisher] (Source: Gynecologic Oncology) Gynecologic Oncology journals http://www.medworm.com/rss/comments.php?id=3205657 Fri, 22 Jan 2010 00:00:00 +0100 3205657 http://www.medworm.com/index.php?rid=3205659&cid=s_35590_6_f&fid=35590&url=http%3A%2F%2Fwww.ncbi.nlm.nih.gov%2Fentrez%2Fquery.fcgi%3Ftmpl%3DNoSidebarfile%26db%3DPubMed%26cmd%3DRetrieve%26list_uids%3D20096921%26dopt%3DAbstract CONCLUSIONS.: Our findings support the hypothesis that metabolic abnormalities or insulin resistance may promote the initiation and progression of endometrial cancer. The effective treatment of type 2 diabetes might contribute to endometrial cancer prevention. PMID: 20096921 [PubMed - as supplied by publisher] (Source: Gynecologic Oncology) Gynecologic Oncology journals http://www.medworm.com/rss/comments.php?id=3205659 Thu, 21 Jan 2010 00:00:00 +0100 3205659 http://www.medworm.com/index.php?rid=3205658&cid=s_35590_6_f&fid=35590&url=http%3A%2F%2Fwww.ncbi.nlm.nih.gov%2Fentrez%2Fquery.fcgi%3Ftmpl%3DNoSidebarfile%26db%3DPubMed%26cmd%3DRetrieve%26list_uids%3D20096922%26dopt%3DAbstract Authors: Di Giorgio A, Cardi M, Sammartino P PMID: 20096922 [PubMed - as supplied by publisher] (Source: Gynecologic Oncology) Gynecologic Oncology journals http://www.medworm.com/rss/comments.php?id=3205658 Thu, 21 Jan 2010 00:00:00 +0100 3205658 http://www.medworm.com/index.php?rid=3201883&cid=s_35590_6_f&fid=35590&url=http%3A%2F%2Fwww.ncbi.nlm.nih.gov%2Fentrez%2Fquery.fcgi%3Ftmpl%3DNoSidebarfile%26db%3DPubMed%26cmd%3DRetrieve%26list_uids%3D20092880%26dopt%3DAbstract CONCLUSION: MRI can be useful in accurately assessing the size of vulvar lesion and groin lymph node metastasis. CE-MRI may be of help in improving local staging. PMID: 20092880 [PubMed - as supplied by publisher] (Source: Gynecologic Oncology) Gynecologic Oncology journals http://www.medworm.com/rss/comments.php?id=3201883 Wed, 20 Jan 2010 00:00:00 +0100 3201883 http://www.medworm.com/index.php?rid=3179494&cid=s_35590_6_f&fid=35590&url=http%3A%2F%2Fwww.ncbi.nlm.nih.gov%2Fentrez%2Fquery.fcgi%3Ftmpl%3DNoSidebarfile%26db%3DPubMed%26cmd%3DRetrieve%26list_uids%3D20074783%26dopt%3DAbstract Authors: Rob L, Pluta M, Robova H PMID: 20074783 [PubMed - as supplied by publisher] (Source: Gynecologic Oncology) Gynecologic Oncology journals http://www.medworm.com/rss/comments.php?id=3179494 Tue, 12 Jan 2010 00:00:00 +0100 3179494 http://www.medworm.com/index.php?rid=3179493&cid=s_35590_6_f&fid=35590&url=http%3A%2F%2Fwww.ncbi.nlm.nih.gov%2Fentrez%2Fquery.fcgi%3Ftmpl%3DNoSidebarfile%26db%3DPubMed%26cmd%3DRetrieve%26list_uids%3D20074784%26dopt%3DAbstract CONCLUSION: These results show correlation between obesity (and overweight) and increased endometrial cell proliferation, and the activation of AKT and ERK1,2. These features could be related with the higher risk to develop type-I EC in overweight and obese women. PMID: 20074784 [PubMed - as supplied by publisher] (Source: Gynecologic Oncology) Gynecologic Oncology journals http://www.medworm.com/rss/comments.php?id=3179493 Tue, 12 Jan 2010 00:00:00 +0100 3179493 http://www.medworm.com/index.php?rid=3179496&cid=s_35590_6_f&fid=35590&url=http%3A%2F%2Fwww.ncbi.nlm.nih.gov%2Fentrez%2Fquery.fcgi%3Ftmpl%3DNoSidebarfile%26db%3DPubMed%26cmd%3DRetrieve%26list_uids%3D20071013%26dopt%3DAbstract CONCLUSIONS: The altered expression of AdipoR1 in invasive breast cancer compared to DCIS suggests that the receptor-binding protein adiponectin might exert growth inhibitory effects that are overcome in transformation of preinvasive to invasive breast cancer. PMID: 20071013 [PubMed - as supplied by publisher] (Source: Gynecologic Oncology) Gynecologic Oncology journals http://www.medworm.com/rss/comments.php?id=3179496 Mon, 11 Jan 2010 00:00:00 +0100 3179496 http://www.medworm.com/index.php?rid=3179495&cid=s_35590_6_f&fid=35590&url=http%3A%2F%2Fwww.ncbi.nlm.nih.gov%2Fentrez%2Fquery.fcgi%3Ftmpl%3DNoSidebarfile%26db%3DPubMed%26cmd%3DRetrieve%26list_uids%3D20071014%26dopt%3DAbstract CONCLUSIONS: Levels of AS are elevated in the urine of patients with EOC and may be of diagnostic and/or prognostic clinical importance. Further studies of uAS as a biomarker for EOC alone or in combination with other markers are warranted. PMID: 20071014 [PubMed - as supplied by publisher] (Source: Gynecologic Oncology) Gynecologic Oncology journals http://www.medworm.com/rss/comments.php?id=3179495 Mon, 11 Jan 2010 00:00:00 +0100 3179495 http://www.medworm.com/index.php?rid=3164833&cid=s_35590_6_f&fid=35590&url=http%3A%2F%2Fwww.ncbi.nlm.nih.gov%2Fentrez%2Fquery.fcgi%3Ftmpl%3DNoSidebarfile%26db%3DPubMed%26cmd%3DRetrieve%26list_uids%3D20061004%26dopt%3DAbstract CONCLUSION: Our meta-analysis provides substantial evidence that bisphosphonates in the adjuvant setting among women with breast cancer do not decrease the number of fractures compared with placebo or no treatment. PMID: 20061004 [PubMed - as supplied by publisher] (Source: Gynecologic Oncology) Gynecologic Oncology journals http://www.medworm.com/rss/comments.php?id=3164833 Fri, 08 Jan 2010 00:00:00 +0100 3164833 http://www.medworm.com/index.php?rid=3164832&cid=s_35590_6_f&fid=35590&url=http%3A%2F%2Fwww.ncbi.nlm.nih.gov%2Fentrez%2Fquery.fcgi%3Ftmpl%3DNoSidebarfile%26db%3DPubMed%26cmd%3DRetrieve%26list_uids%3D20061005%26dopt%3DAbstract CONCLUSION(S): Node-positive patients were heterogeneous, with different prognoses and recurrence patterns according to clinicopathologic risk factors. Further clinical trials are warranted to develop adjuvant treatment strategies individualized to each risk group. PMID: 20061005 [PubMed - as supplied by publisher] (Source: Gynecologic Oncology) Gynecologic Oncology journals http://www.medworm.com/rss/comments.php?id=3164832 Fri, 08 Jan 2010 00:00:00 +0100 3164832 http://www.medworm.com/index.php?rid=3164834&cid=s_35590_6_f&fid=35590&url=http%3A%2F%2Fwww.ncbi.nlm.nih.gov%2Fentrez%2Fquery.fcgi%3Ftmpl%3DNoSidebarfile%26db%3DPubMed%26cmd%3DRetrieve%26list_uids%3D20060575%26dopt%3DAbstract CONCLUSIONS.: NICD was frequently expressed in ovarian cancer cell lines and human ovarian cancer specimens. Importantly, depletion of Notch 1 led to growth inhibition of ovarian cancer cells. These findings support the hypothesis that Notch 1 plays a role in ovarian cancer proliferation, encouraging the investigation of this pathway as a therapeutic target. PMID: 20060575 [PubMed - as supplied by publisher] (Source: Gynecologic Oncology) Gynecologic Oncology journals http://www.medworm.com/rss/comments.php?id=3164834 Thu, 07 Jan 2010 00:00:00 +0100 3164834 http://www.medworm.com/index.php?rid=3164835&cid=s_35590_6_f&fid=35590&url=http%3A%2F%2Fwww.ncbi.nlm.nih.gov%2Fentrez%2Fquery.fcgi%3Ftmpl%3DNoSidebarfile%26db%3DPubMed%26cmd%3DRetrieve%26list_uids%3D20060158%26dopt%3DAbstract CONCLUSION: The number of involved sites outside the corpus uterine for stage IIIA seems to be a strong negative prognostic factor for stage IIIA endometrial carcinoma. PMID: 20060158 [PubMed - as supplied by publisher] (Source: Gynecologic Oncology) Gynecologic Oncology journals http://www.medworm.com/rss/comments.php?id=3164835 Wed, 06 Jan 2010 00:00:00 +0100 3164835 http://www.medworm.com/index.php?rid=3156767&cid=s_35590_6_f&fid=35590&url=http%3A%2F%2Fwww.ncbi.nlm.nih.gov%2Fentrez%2Fquery.fcgi%3Ftmpl%3DNoSidebarfile%26db%3DPubMed%26cmd%3DRetrieve%26list_uids%3D20056266%26dopt%3DAbstract Authors: Guarneri V, Piacentini F, Barbieri E, Conte PF Ovarian cancer is the second most common gynaecological malignancy, and represents the leading cause of gynecologic cancer-related death in Europe and United States. The majority of the cases are in fact diagnosed in advanced stage, with limited chance to be cured. Optimal management of advanced ovarian cancer includes histopathological diagnosis, accurate surgical staging, debulking surgery and platinum-based chemotherapy. The combination of carboplatin and paclitaxel is commonly recognised as the standard regimen because of tolerability and activity. Intraperitoneal chemotherapy provides superior efficacy results, but its use is still controversial because of poor tolerability and compliance. Unfortunately, despite its chemosens... Gynecologic Oncology journals http://www.medworm.com/rss/comments.php?id=3156767 Tue, 05 Jan 2010 00:00:00 +0100 3156767 http://www.medworm.com/index.php?rid=3156766&cid=s_35590_6_f&fid=35590&url=http%3A%2F%2Fwww.ncbi.nlm.nih.gov%2Fentrez%2Fquery.fcgi%3Ftmpl%3DNoSidebarfile%26db%3DPubMed%26cmd%3DRetrieve%26list_uids%3D20056267%26dopt%3DAbstract CONCLUSIONS: VEGF polymorphisms were found to be significantly related with serum VEGF levels. The AGCGC haplotype was found to be independently associated with improved PFS. PMID: 20056267 [PubMed - as supplied by publisher] (Source: Gynecologic Oncology) Gynecologic Oncology journals http://www.medworm.com/rss/comments.php?id=3156766 Tue, 05 Jan 2010 00:00:00 +0100 3156766 http://www.medworm.com/index.php?rid=3156765&cid=s_35590_6_f&fid=35590&url=http%3A%2F%2Fwww.ncbi.nlm.nih.gov%2Fentrez%2Fquery.fcgi%3Ftmpl%3DNoSidebarfile%26db%3DPubMed%26cmd%3DRetrieve%26list_uids%3D20056268%26dopt%3DAbstract CONCLUSIONS: LPA is a potent modulator of cellular proliferation and invasion for EC cells. It also has the capacity to stimulate the secretion/activity of uPA and MMP-7. Those results suggest that LPA is a bioactive modulator of EC microenvironment and may have a distinct regulation mechanism as observed in epithelial ovarian cancer. PMID: 20056268 [PubMed - as supplied by publisher] (Source: Gynecologic Oncology) Gynecologic Oncology journals http://www.medworm.com/rss/comments.php?id=3156765 Tue, 05 Jan 2010 00:00:00 +0100 3156765 http://www.medworm.com/index.php?rid=3149605&cid=s_35590_6_f&fid=35590&url=http%3A%2F%2Fwww.ncbi.nlm.nih.gov%2Fentrez%2Fquery.fcgi%3Ftmpl%3DNoSidebarfile%26db%3DPubMed%26cmd%3DRetrieve%26list_uids%3D20051287%26dopt%3DAbstract CONCLUSIONS: CAIX is upregulated in ovarian cancer and serum CAIX could be a marker to stratify patients for therapy response. However, CAIX serum levels did not change significantly during first-line therapy and were not prognostically relevant. Based on the findings of the current study, CAIX cannot be recommended for therapy monitoring in this context. PMID: 20051287 [PubMed - as supplied by publisher] (Source: Gynecologic Oncology) Gynecologic Oncology journals http://www.medworm.com/rss/comments.php?id=3149605 Sun, 03 Jan 2010 00:00:00 +0100 3149605 http://www.medworm.com/index.php?rid=3149604&cid=s_35590_6_f&fid=35590&url=http%3A%2F%2Fwww.ncbi.nlm.nih.gov%2Fentrez%2Fquery.fcgi%3Ftmpl%3DNoSidebarfile%26db%3DPubMed%26cmd%3DRetrieve%26list_uids%3D20051288%26dopt%3DAbstract CONCLUSION: Intravenous iron is an alternative treatment for anemic gynecologic cancer patients receiving platinum-based chemotherapy and reduces the incidence of RBC transfusion without serious adverse events. PMID: 20051288 [PubMed - as supplied by publisher] (Source: Gynecologic Oncology) Gynecologic Oncology journals http://www.medworm.com/rss/comments.php?id=3149604 Sun, 03 Jan 2010 00:00:00 +0100 3149604 http://www.medworm.com/index.php?rid=3067890&cid=s_35590_6_f&fid=35590&url=http%3A%2F%2Fwww.ncbi.nlm.nih.gov%2Fentrez%2Fquery.fcgi%3Ftmpl%3DNoSidebarfile%26db%3DPubMed%26cmd%3DRetrieve%26list_uids%3D19962037%26dopt%3DAbstract Authors: Singh DK, Lurain JR PMID: 19962037 [PubMed - in process] (Source: Gynecologic Oncology) Gynecologic Oncology journals http://www.medworm.com/rss/comments.php?id=3067890 Wed, 09 Dec 2009 07:12:11 +0100 3067890 http://www.medworm.com/index.php?rid=3067888&cid=s_35590_6_f&fid=35590&url=http%3A%2F%2Fwww.ncbi.nlm.nih.gov%2Fentrez%2Fquery.fcgi%3Ftmpl%3DNoSidebarfile%26db%3DPubMed%26cmd%3DRetrieve%26list_uids%3D19962741%26dopt%3DAbstract Authors: Hsu WC, Chung NN, Chen YC PMID: 19962741 [PubMed - as supplied by publisher] (Source: Gynecologic Oncology) Gynecologic Oncology journals http://www.medworm.com/rss/comments.php?id=3067888 Thu, 03 Dec 2009 00:00:00 +0100 3067888 http://www.medworm.com/index.php?rid=3067889&cid=s_35590_6_f&fid=35590&url=http%3A%2F%2Fwww.ncbi.nlm.nih.gov%2Fentrez%2Fquery.fcgi%3Ftmpl%3DNoSidebarfile%26db%3DPubMed%26cmd%3DRetrieve%26list_uids%3D19962178%26dopt%3DAbstract CONCLUSION: MPO and iNOS are colocalized to the same cells in EOC but not in the normal ovarian epithelium. Silencing of either MPO or iNOS significantly induced apoptosis, highlighting their role as a redox switch that regulates apoptosis in EOC. Understanding the mechanisms by which MPO functions as a redox switch in regulating apoptosis in EOC may lead to future diagnostic tools and therapeutic interventions. PMID: 19962178 [PubMed - as supplied by publisher] (Source: Gynecologic Oncology) Gynecologic Oncology journals http://www.medworm.com/rss/comments.php?id=3067889 Wed, 02 Dec 2009 00:00:00 +0100 3067889 http://www.medworm.com/index.php?rid=3058218&cid=s_35590_6_f&fid=35590&url=http%3A%2F%2Fwww.ncbi.nlm.nih.gov%2Fentrez%2Fquery.fcgi%3Ftmpl%3DNoSidebarfile%26db%3DPubMed%26cmd%3DRetrieve%26list_uids%3D19959214%26dopt%3DAbstract CONCLUSIONS: Fas and TRAIL loss is associated with dedifferentiation and worse prognosis. Expression of DR4, DR5, caspase 8 and c-FLIP by most ovarian cancers does not correlate with survival. High c-FLIP expression should be taken into account for death receptor targeted therapies. PMID: 19959214 [PubMed - as supplied by publisher] (Source: Gynecologic Oncology) Gynecologic Oncology journals http://www.medworm.com/rss/comments.php?id=3058218 Wed, 02 Dec 2009 00:00:00 +0100 3058218 http://www.medworm.com/index.php?rid=3058216&cid=s_35590_6_f&fid=35590&url=http%3A%2F%2Fwww.ncbi.nlm.nih.gov%2Fentrez%2Fquery.fcgi%3Ftmpl%3DNoSidebarfile%26db%3DPubMed%26cmd%3DRetrieve%26list_uids%3D19959216%26dopt%3DAbstract Authors: Estape R, Lambrou N PMID: 19959216 [PubMed - as supplied by publisher] (Source: Gynecologic Oncology) Gynecologic Oncology journals http://www.medworm.com/rss/comments.php?id=3058216 Wed, 02 Dec 2009 00:00:00 +0100 3058216 http://www.medworm.com/index.php?rid=3058227&cid=s_35590_6_f&fid=35590&url=http%3A%2F%2Fwww.ncbi.nlm.nih.gov%2Fentrez%2Fquery.fcgi%3Ftmpl%3DNoSidebarfile%26db%3DPubMed%26cmd%3DRetrieve%26list_uids%3D19959210%26dopt%3DAbstract Authors: Irminger-Finger I Breast cancer is the leading cause of cancer death in women. Ovarian cancer, although less frequent, is detected very late, and survival is correlated to early detection. Therefore, better methods for early detection would help to increase the number of survivors. The incidence of young women diagnosed with breast cancer is increasing. These women and women who are at risk because of a family history of breast cancer would benefit from more accurate and less invasive screening methods than those in place today. A blood test based on BARD1, a protein that interacts with the breast cancer gene product BRCA1, is a promising candidate for fulfilling these conditions. The science behind BARD1 and its role in breast and ovarian cancer is explained in this article. ... Gynecologic Oncology journals http://www.medworm.com/rss/comments.php?id=3058227 Tue, 01 Dec 2009 00:00:00 +0100 3058227 http://www.medworm.com/index.php?rid=3058221&cid=s_35590_6_f&fid=35590&url=http%3A%2F%2Fwww.ncbi.nlm.nih.gov%2Fentrez%2Fquery.fcgi%3Ftmpl%3DNoSidebarfile%26db%3DPubMed%26cmd%3DRetrieve%26list_uids%3D19959211%26dopt%3DAbstract CONCLUSIONS: The dose modifications utilized in this study allowed for completion of 6 cycles of adjuvant IP chemotherapy in 83% of patients. Choice of catheter type did not affect completion rates. Continued monitoring of outcomes is planned to compare PFS and OS. The high completion rate may increase acceptance of IP chemotherapy in the community setting. PMID: 19959211 [PubMed - as supplied by publisher] (Source: Gynecologic Oncology) Gynecologic Oncology journals http://www.medworm.com/rss/comments.php?id=3058221 Tue, 01 Dec 2009 00:00:00 +0100 3058221 http://www.medworm.com/index.php?rid=3058220&cid=s_35590_6_f&fid=35590&url=http%3A%2F%2Fwww.ncbi.nlm.nih.gov%2Fentrez%2Fquery.fcgi%3Ftmpl%3DNoSidebarfile%26db%3DPubMed%26cmd%3DRetrieve%26list_uids%3D19959212%26dopt%3DAbstract Authors: Kandalaft LE, Singh N, Liao JB, Facciabene A, Berek JS, Powell DJ, Coukos G In the past decade we have witnessed important advances in the treatment of gynecological cancers and have recognized their potential immunogenicity. This has opened the door to explore immune therapy not only in HPV-induced cancers but also in ovarian and endometrial cancers. Here we will review the off-target immune effects of select chemotherapy drugs commonly used to treat gynecologic cancers and novel tools that can stimulate both the adaptive and innate immune mechanisms such as novel pleiotropic cytokines, Toll-like receptors, and powerful antibodies that can target inhibitory checkpoints, thereby activating effector cellular immune mechanisms and neutralizing suppressor cells. We will also revi... Gynecologic Oncology journals http://www.medworm.com/rss/comments.php?id=3058220 Tue, 01 Dec 2009 00:00:00 +0100 3058220 http://www.medworm.com/index.php?rid=3058219&cid=s_35590_6_f&fid=35590&url=http%3A%2F%2Fwww.ncbi.nlm.nih.gov%2Fentrez%2Fquery.fcgi%3Ftmpl%3DNoSidebarfile%26db%3DPubMed%26cmd%3DRetrieve%26list_uids%3D19959213%26dopt%3DAbstract CONCLUSION: These results suggest that this sequential regimen using weekly paclitaxel represents an efficacious and well-tolerated regimen. A randomized study comparing this new schedule with the conventional 3-week protocol is warranted. PMID: 19959213 [PubMed - as supplied by publisher] (Source: Gynecologic Oncology) Gynecologic Oncology journals http://www.medworm.com/rss/comments.php?id=3058219 Tue, 01 Dec 2009 00:00:00 +0100 3058219 http://www.medworm.com/index.php?rid=3058217&cid=s_35590_6_f&fid=35590&url=http%3A%2F%2Fwww.ncbi.nlm.nih.gov%2Fentrez%2Fquery.fcgi%3Ftmpl%3DNoSidebarfile%26db%3DPubMed%26cmd%3DRetrieve%26list_uids%3D19959215%26dopt%3DAbstract CONCLUSIONS: In our study population, introduction of the RMI would improve the management of adnexal masses, with a higher percentage of ovarian cancer patients that are operated by a gynecologic oncologist. At the same time, referral of patients with non-invasive (benign and borderline) lesions would be reduced. PMID: 19959215 [PubMed - as supplied by publisher] (Source: Gynecologic Oncology) Gynecologic Oncology journals http://www.medworm.com/rss/comments.php?id=3058217 Tue, 01 Dec 2009 00:00:00 +0100 3058217 http://www.medworm.com/index.php?rid=3058215&cid=s_35590_6_f&fid=35590&url=http%3A%2F%2Fwww.ncbi.nlm.nih.gov%2Fentrez%2Fquery.fcgi%3Ftmpl%3DNoSidebarfile%26db%3DPubMed%26cmd%3DRetrieve%26list_uids%3D19959217%26dopt%3DAbstract CONCLUSION: The observation that these combinations of loci are associated in different populations supports their importance in cervical cancer development although the opposite directions of the effect call for clarification. The polymorphisms studied might not be the functional variants per se, but linked to those exerting a functional effect. The opposite associations in the two populations could then be explained by differences in linkage disequilibrium and population structure. PMID: 19959217 [PubMed - as supplied by publisher] (Source: Gynecologic Oncology) Gynecologic Oncology journals http://www.medworm.com/rss/comments.php?id=3058215 Tue, 01 Dec 2009 00:00:00 +0100 3058215 http://www.medworm.com/index.php?rid=3004470&cid=s_35590_6_f&fid=35590&url=http%3A%2F%2Fwww.ncbi.nlm.nih.gov%2Fentrez%2Fquery.fcgi%3Ftmpl%3DNoSidebarfile%26db%3DPubMed%26cmd%3DRetrieve%26list_uids%3D19552945%26dopt%3DAbstract CONCLUSIONS: This survey provides an update on sexual debut and behavior in young adults in some European countries. Estimated age at sexual debut ranged between 16 and 18 years and appeared to be later in girls than in boys. The proportion of girls sexually active before the age of 15 years was low (</=11.9%). Almost one-third of young women did not use a condom. This survey provides useful information to support current or planned HPV vaccination programs in Europe. PMID: 19552945 [PubMed - in process] (Source: Gynecologic Oncology) Gynecologic Oncology journals http://www.medworm.com/rss/comments.php?id=3004470 Wed, 18 Nov 2009 22:12:08 +0100 3004470 http://www.medworm.com/index.php?rid=2963641&cid=s_35590_6_f&fid=35590&url=http%3A%2F%2Fwww.ncbi.nlm.nih.gov%2Fentrez%2Fquery.fcgi%3Ftmpl%3DNoSidebarfile%26db%3DPubMed%26cmd%3DRetrieve%26list_uids%3D19883850%26dopt%3DAbstract Authors: Li AJ PMID: 19883850 [PubMed - in process] (Source: Gynecologic Oncology) Gynecologic Oncology journals http://www.medworm.com/rss/comments.php?id=2963641 Thu, 05 Nov 2009 22:58:04 +0100 2963641 http://www.medworm.com/index.php?rid=2891176&cid=s_35590_6_f&fid=35590&url=http%3A%2F%2Fwww.ncbi.nlm.nih.gov%2Fentrez%2Fquery.fcgi%3Ftmpl%3DNoSidebarfile%26db%3DPubMed%26cmd%3DRetrieve%26list_uids%3D19822256%26dopt%3DAbstract Authors: Nelson BH PMID: 19822256 [PubMed - in process] (Source: Gynecologic Oncology) Gynecologic Oncology journals http://www.medworm.com/rss/comments.php?id=2891176 Wed, 14 Oct 2009 18:36:19 +0100 2891176 http://www.medworm.com/index.php?rid=2891175&cid=s_35590_6_f&fid=35590&url=http%3A%2F%2Fwww.ncbi.nlm.nih.gov%2Fentrez%2Fquery.fcgi%3Ftmpl%3DNoSidebarfile%26db%3DPubMed%26cmd%3DRetrieve%26list_uids%3D19822354%26dopt%3DAbstract Authors: Karam AK, Karlan BY PMID: 19822354 [PubMed - as supplied by publisher] (Source: Gynecologic Oncology) Gynecologic Oncology journals http://www.medworm.com/rss/comments.php?id=2891175 Fri, 09 Oct 2009 23:00:00 +0100 2891175 http://www.medworm.com/index.php?rid=2891174&cid=s_35590_6_f&fid=35590&url=http%3A%2F%2Fwww.ncbi.nlm.nih.gov%2Fentrez%2Fquery.fcgi%3Ftmpl%3DNoSidebarfile%26db%3DPubMed%26cmd%3DRetrieve%26list_uids%3D19822355%26dopt%3DAbstract CONCLUSIONS: We find that metformin is a potent inhibitor of cell proliferation in endometrial cancer cell lines. This effect is partially mediated through AMPK activation and subsequent inhibition of the mTOR pathway. This work should provide the scientific foundation for future investigation of metformin as a strategy for endometrial cancer prevention and treatment. PMID: 19822355 [PubMed - as supplied by publisher] (Source: Gynecologic Oncology) Gynecologic Oncology journals http://www.medworm.com/rss/comments.php?id=2891174 Fri, 09 Oct 2009 23:00:00 +0100 2891174 http://www.medworm.com/index.php?rid=2891173&cid=s_35590_6_f&fid=35590&url=http%3A%2F%2Fwww.ncbi.nlm.nih.gov%2Fentrez%2Fquery.fcgi%3Ftmpl%3DNoSidebarfile%26db%3DPubMed%26cmd%3DRetrieve%26list_uids%3D19822356%26dopt%3DAbstract DISCUSSION: Measurement of hyperglycosylated hCG or invasiveness is a critical step in management of invasive gestational trophoblastic disease. Quiescent of inactive gestational trophoblastic disease requires no therapy. Minimally invasive disease in chemorefractory. The USA hCG Reference Service experience suggests waiting until hCG exceeds 3000 IU/L before commencing any chemotherapy. PMID: 19822356 [PubMed - as supplied by publisher] (Source: Gynecologic Oncology) Gynecologic Oncology journals http://www.medworm.com/rss/comments.php?id=2891173 Fri, 09 Oct 2009 23:00:00 +0100 2891173 http://www.medworm.com/index.php?rid=2891172&cid=s_35590_6_f&fid=35590&url=http%3A%2F%2Fwww.ncbi.nlm.nih.gov%2Fentrez%2Fquery.fcgi%3Ftmpl%3DNoSidebarfile%26db%3DPubMed%26cmd%3DRetrieve%26list_uids%3D19822357%26dopt%3DAbstract CONCLUSIONS: These data suggest LDL is a significant predictor of clinical outcome, and warrant the further study of lipoproteins and statins on epithelial ovarian cancer biology. PMID: 19822357 [PubMed - as supplied by publisher] (Source: Gynecologic Oncology) Gynecologic Oncology journals http://www.medworm.com/rss/comments.php?id=2891172 Fri, 09 Oct 2009 23:00:00 +0100 2891172 http://www.medworm.com/index.php?rid=2891171&cid=s_35590_6_f&fid=35590&url=http%3A%2F%2Fwww.ncbi.nlm.nih.gov%2Fentrez%2Fquery.fcgi%3Ftmpl%3DNoSidebarfile%26db%3DPubMed%26cmd%3DRetrieve%26list_uids%3D19822358%26dopt%3DAbstract CONCLUSIONS: A subset of ovarian carcinoma patients with an excellent outcome can be identified based on tumor type (endometrioid or mucinous) and stage (Ia or Ib). Type is more reproducibly assigned than grade and identifies a larger cohort of women with stage I/II ovarian carcinoma with favorable outcomes (12.2% vs. 6.5%), and therefore is superior to grade in estimating risk of death from ovarian carcinoma. PMID: 19822358 [PubMed - as supplied by publisher] (Source: Gynecologic Oncology) Gynecologic Oncology journals http://www.medworm.com/rss/comments.php?id=2891171 Fri, 09 Oct 2009 23:00:00 +0100 2891171 http://www.medworm.com/index.php?rid=2891170&cid=s_35590_6_f&fid=35590&url=http%3A%2F%2Fwww.ncbi.nlm.nih.gov%2Fentrez%2Fquery.fcgi%3Ftmpl%3DNoSidebarfile%26db%3DPubMed%26cmd%3DRetrieve%26list_uids%3D19822359%26dopt%3DAbstract Authors: Einenkel J, Wuttke P, Horn K PMID: 19822359 [PubMed - as supplied by publisher] (Source: Gynecologic Oncology) Gynecologic Oncology journals http://www.medworm.com/rss/comments.php?id=2891170 Fri, 09 Oct 2009 23:00:00 +0100 2891170 http://www.medworm.com/index.php?rid=2891177&cid=s_35590_6_f&fid=35590&url=http%3A%2F%2Fwww.ncbi.nlm.nih.gov%2Fentrez%2Fquery.fcgi%3Ftmpl%3DNoSidebarfile%26db%3DPubMed%26cmd%3DRetrieve%26list_uids%3D19819540%26dopt%3DAbstract CONCLUSION: The priority of routine vaccination programmes must be to target girls and young women, with catch-up programmes that extend to age 25/26 when resources allow. For sexually active women over the age of 25, HPV vaccination can be considered on an individual basis, as most will have the potential to benefit from vaccination. PMID: 19819540 [PubMed - as supplied by publisher] (Source: Gynecologic Oncology) Gynecologic Oncology journals http://www.medworm.com/rss/comments.php?id=2891177 Thu, 08 Oct 2009 23:00:00 +0100 2891177 http://www.medworm.com/index.php?rid=2891179&cid=s_35590_6_f&fid=35590&url=http%3A%2F%2Fwww.ncbi.nlm.nih.gov%2Fentrez%2Fquery.fcgi%3Ftmpl%3DNoSidebarfile%26db%3DPubMed%26cmd%3DRetrieve%26list_uids%3D19818996%26dopt%3DAbstract CONCLUSIONS: CA125 level after 6 cycles of adjuvant chemotherapy is a strong independent prognostic factor for high-risk, early stage epithelial ovarian cancer after achieving a complete response. PMID: 19818996 [PubMed - as supplied by publisher] (Source: Gynecologic Oncology) Gynecologic Oncology journals http://www.medworm.com/rss/comments.php?id=2891179 Wed, 07 Oct 2009 23:00:00 +0100 2891179 http://www.medworm.com/index.php?rid=2891178&cid=s_35590_6_f&fid=35590&url=http%3A%2F%2Fwww.ncbi.nlm.nih.gov%2Fentrez%2Fquery.fcgi%3Ftmpl%3DNoSidebarfile%26db%3DPubMed%26cmd%3DRetrieve%26list_uids%3D19818997%26dopt%3DAbstract CONCLUSIONS: AR allelotype length did not correlate with survival in this statistically representative cohort of patients with BRCA1/2 mutations. Potential associations between short AR and outcome in BRCA2-associated ovarian cancers remain to be determined. PMID: 19818997 [PubMed - as supplied by publisher] (Source: Gynecologic Oncology) Gynecologic Oncology journals http://www.medworm.com/rss/comments.php?id=2891178 Wed, 07 Oct 2009 23:00:00 +0100 2891178 http://www.medworm.com/index.php?rid=2891180&cid=s_35590_6_f&fid=35590&url=http%3A%2F%2Fwww.ncbi.nlm.nih.gov%2Fentrez%2Fquery.fcgi%3Ftmpl%3DNoSidebarfile%26db%3DPubMed%26cmd%3DRetrieve%26list_uids%3D19818481%26dopt%3DAbstract CONCLUSIONS: P-chem did not affect reproductive outcomes for patients with Hr-HM. Patients allowed to become pregnant again in both groups had high rates of live births associated with normal pregnancies. Chances of a subsequent pregnancy were higher in the low age and low parity subgroups. PMID: 19818481 [PubMed - as supplied by publisher] (Source: Gynecologic Oncology) Gynecologic Oncology journals http://www.medworm.com/rss/comments.php?id=2891180 Tue, 06 Oct 2009 23:00:00 +0100 2891180 http://www.medworm.com/index.php?rid=2880013&cid=s_35590_6_f&fid=35590&url=http%3A%2F%2Fwww.ncbi.nlm.nih.gov%2Fentrez%2Fquery.fcgi%3Ftmpl%3DNoSidebarfile%26db%3DPubMed%26cmd%3DRetrieve%26list_uids%3D19811809%26dopt%3DAbstract CONCLUSION: The impact on patient outcome is minimal and it does not prove to be cost and time effective when submitting the entire LN dissection specimen in gynecologic malignancies. However, this method could be justified in selective cases in which the manual node dissection does not reveal an adequate number of LNs. PMID: 19811809 [PubMed - as supplied by publisher] (Source: Gynecologic Oncology) Gynecologic Oncology journals http://www.medworm.com/rss/comments.php?id=2880013 Mon, 05 Oct 2009 23:00:00 +0100 2880013 http://www.medworm.com/index.php?rid=2880012&cid=s_35590_6_f&fid=35590&url=http%3A%2F%2Fwww.ncbi.nlm.nih.gov%2Fentrez%2Fquery.fcgi%3Ftmpl%3DNoSidebarfile%26db%3DPubMed%26cmd%3DRetrieve%26list_uids%3D19811810%26dopt%3DAbstract CONCLUSION: To date no biomarkers for early diagnosis or prognostication in ovarian cancer have been found using proteomics. We speculate that it would be interesting to investigate the tissue proteome in an attempt to overcome acute phase reactants and to facilitate the discovery of real tumor-specific biomarkers instead of the identification of secondary protein changes. PMID: 19811810 [PubMed - as supplied by publisher] (Source: Gynecologic Oncology) Gynecologic Oncology journals http://www.medworm.com/rss/comments.php?id=2880012 Sun, 04 Oct 2009 23:00:00 +0100 2880012 http://www.medworm.com/index.php?rid=2880011&cid=s_35590_6_f&fid=35590&url=http%3A%2F%2Fwww.ncbi.nlm.nih.gov%2Fentrez%2Fquery.fcgi%3Ftmpl%3DNoSidebarfile%26db%3DPubMed%26cmd%3DRetrieve%26list_uids%3D19811811%26dopt%3DAbstract CONCLUSION: Sunitinib fails to achieve sufficient objective response or sustained disease stabilization as second- or third-line treatment for uterine leiomyosarcoma. PMID: 19811811 [PubMed - as supplied by publisher] (Source: Gynecologic Oncology) Gynecologic Oncology journals http://www.medworm.com/rss/comments.php?id=2880011 Sun, 04 Oct 2009 23:00:00 +0100 2880011 http://www.medworm.com/index.php?rid=2872863&cid=s_35590_6_f&fid=35590&url=http%3A%2F%2Fwww.ncbi.nlm.nih.gov%2Fentrez%2Fquery.fcgi%3Ftmpl%3DNoSidebarfile%26db%3DPubMed%26cmd%3DRetrieve%26list_uids%3D19804900%26dopt%3DAbstract CONCLUSIONS: SHetA2, but not cisplatin or paclitaxel, can overcome resistance of ovarian cancer cells to TNFalpha and TRAIL without increasing sensitivity of normal cells to these death receptor ligands. PMID: 19804900 [PubMed - as supplied by publisher] (Source: Gynecologic Oncology) Gynecologic Oncology journals http://www.medworm.com/rss/comments.php?id=2872863 Fri, 02 Oct 2009 23:00:00 +0100 2872863 http://www.medworm.com/index.php?rid=2872862&cid=s_35590_6_f&fid=35590&url=http%3A%2F%2Fwww.ncbi.nlm.nih.gov%2Fentrez%2Fquery.fcgi%3Ftmpl%3DNoSidebarfile%26db%3DPubMed%26cmd%3DRetrieve%26list_uids%3D19804901%26dopt%3DAbstract CONCLUSIONS: Combination of paclitaxel and bevacizumab is feasible and demonstrates an acceptable toxicity profile and a high response rate. These observations should be useful in planning future clinical trials with this combination therapy. PMID: 19804901 [PubMed - as supplied by publisher] (Source: Gynecologic Oncology) Gynecologic Oncology journals http://www.medworm.com/rss/comments.php?id=2872862 Fri, 02 Oct 2009 23:00:00 +0100 2872862 http://www.medworm.com/index.php?rid=2872861&cid=s_35590_6_f&fid=35590&url=http%3A%2F%2Fwww.ncbi.nlm.nih.gov%2Fentrez%2Fquery.fcgi%3Ftmpl%3DNoSidebarfile%26db%3DPubMed%26cmd%3DRetrieve%26list_uids%3D19804902%26dopt%3DAbstract CONCLUSION: Pemetrexed has minimal activity in the treatment of recurrent or persistent endometrial carcinoma at the dose and schedule tested. PMID: 19804902 [PubMed - as supplied by publisher] (Source: Gynecologic Oncology) Gynecologic Oncology journals http://www.medworm.com/rss/comments.php?id=2872861 Fri, 02 Oct 2009 23:00:00 +0100 2872861 http://www.medworm.com/index.php?rid=2866297&cid=s_35590_6_f&fid=35590&url=http%3A%2F%2Fwww.ncbi.nlm.nih.gov%2Fentrez%2Fquery.fcgi%3Ftmpl%3DNoSidebarfile%26db%3DPubMed%26cmd%3DRetrieve%26list_uids%3D19801166%26dopt%3DAbstract CONCLUSIONS: In this study, we confirmed the feasibility of the SLN technique by NOTES. It can be considered as a potential alternative to reduce morbidity during staging procedures for gynecologic malignancies. Prospective randomized series are necessary to establish the safety and the real benefits of this new technique. PMID: 19801166 [PubMed - as supplied by publisher] (Source: Gynecologic Oncology) Gynecologic Oncology journals http://www.medworm.com/rss/comments.php?id=2866297 Thu, 01 Oct 2009 23:00:00 +0100 2866297 http://www.medworm.com/index.php?rid=2866300&cid=s_35590_6_f&fid=35590&url=http%3A%2F%2Fwww.ncbi.nlm.nih.gov%2Fentrez%2Fquery.fcgi%3Ftmpl%3DNoSidebarfile%26db%3DPubMed%26cmd%3DRetrieve%26list_uids%3D19800108%26dopt%3DAbstract CONCLUSION: Using a MS based proteomics approach we have shown that expression of CD70 is associated with cisplatin resistance in ovarian cancer cell lines. Follow-up examination of these tumor cell line findings in clinical tumor specimens with available pathology staging and cisplatin treatment history is warranted. PMID: 19800108 [PubMed - as supplied by publisher] (Source: Gynecologic Oncology) Gynecologic Oncology journals http://www.medworm.com/rss/comments.php?id=2866300 Wed, 30 Sep 2009 23:00:00 +0100 2866300 http://www.medworm.com/index.php?rid=2866299&cid=s_35590_6_f&fid=35590&url=http%3A%2F%2Fwww.ncbi.nlm.nih.gov%2Fentrez%2Fquery.fcgi%3Ftmpl%3DNoSidebarfile%26db%3DPubMed%26cmd%3DRetrieve%26list_uids%3D19800673%26dopt%3DAbstract CONCLUSIONS: FDR gemcitabine+carboplatin on a 21-day schedule was active and produced no unusual safety signals in patients with Pt-S OC. PMID: 19800673 [PubMed - as supplied by publisher] (Source: Gynecologic Oncology) Gynecologic Oncology journals http://www.medworm.com/rss/comments.php?id=2866299 Wed, 30 Sep 2009 23:00:00 +0100 2866299 http://www.medworm.com/index.php?rid=2866298&cid=s_35590_6_f&fid=35590&url=http%3A%2F%2Fwww.ncbi.nlm.nih.gov%2Fentrez%2Fquery.fcgi%3Ftmpl%3DNoSidebarfile%26db%3DPubMed%26cmd%3DRetrieve%26list_uids%3D19800674%26dopt%3DAbstract CONCLUSIONS: Thus, hospital type did not influence the outcomes of first-line chemotherapy in ovarian cancer patients. However, overall survival was better in hospitals with 2 or more medical oncologists and in hospitals with a high ovarian cancer patient-volume, suggesting differences in second-line chemotherapy. PMID: 19800674 [PubMed - as supplied by publisher] (Source: Gynecologic Oncology) Gynecologic Oncology journals http://www.medworm.com/rss/comments.php?id=2866298 Wed, 30 Sep 2009 23:00:00 +0100 2866298 http://www.medworm.com/index.php?rid=2752854&cid=s_35590_6_f&fid=35590&url=http%3A%2F%2Fwww.ncbi.nlm.nih.gov%2Fentrez%2Fquery.fcgi%3Ftmpl%3DNoSidebarfile%26db%3DPubMed%26cmd%3DRetrieve%26list_uids%3D19716938%26dopt%3DAbstract Authors: Russell AH PMID: 19716938 [PubMed - in process] (Source: Gynecologic Oncology) Gynecologic Oncology journals http://www.medworm.com/rss/comments.php?id=2752854 Wed, 02 Sep 2009 06:52:07 +0100 2752854 http://www.medworm.com/index.php?rid=2752853&cid=s_35590_6_f&fid=35590&url=http%3A%2F%2Fwww.ncbi.nlm.nih.gov%2Fentrez%2Fquery.fcgi%3Ftmpl%3DNoSidebarfile%26db%3DPubMed%26cmd%3DRetrieve%26list_uids%3D19716939%26dopt%3DAbstract Authors: Temin S, PMID: 19716939 [PubMed - in process] (Source: Gynecologic Oncology) Gynecologic Oncology journals http://www.medworm.com/rss/comments.php?id=2752853 Wed, 02 Sep 2009 06:52:04 +0100 2752853 http://www.medworm.com/index.php?rid=2671425&cid=s_35590_6_f&fid=35590&url=http%3A%2F%2Fwww.ncbi.nlm.nih.gov%2Fentrez%2Fquery.fcgi%3Ftmpl%3DNoSidebarfile%26db%3DPubMed%26cmd%3DRetrieve%26list_uids%3D19647129%26dopt%3DAbstract Authors: Duska LR PMID: 19647129 [PubMed - in process] (Source: Gynecologic Oncology) Gynecologic Oncology journals http://www.medworm.com/rss/comments.php?id=2671425 Wed, 05 Aug 2009 16:08:05 +0100 2671425 http://www.medworm.com/index.php?rid=2603358&cid=s_35590_6_f&fid=35590&url=http%3A%2F%2Fwww.ncbi.nlm.nih.gov%2Fentrez%2Fquery.fcgi%3Ftmpl%3DNoSidebarfile%26db%3DPubMed%26cmd%3DRetrieve%26list_uids%3D19573698%26dopt%3DAbstract Authors: Bristow RE PMID: 19573698 [PubMed - indexed for MEDLINE] (Source: Gynecologic Oncology) Gynecologic Oncology journals http://www.medworm.com/rss/comments.php?id=2603358 Thu, 16 Jul 2009 08:56:31 +0100 2603358 http://www.medworm.com/index.php?rid=2603357&cid=s_35590_6_f&fid=35590&url=http%3A%2F%2Fwww.ncbi.nlm.nih.gov%2Fentrez%2Fquery.fcgi%3Ftmpl%3DNoSidebarfile%26db%3DPubMed%26cmd%3DRetrieve%26list_uids%3D19573699%26dopt%3DAbstract Authors: Verleye L, Ottevanger PB, Vergote I The majority of ovarian cancer patients are diagnosed with advanced-stage disease, for which standard treatment consists of cytoreductive surgery and platinum-based chemotherapy. As the maximum diameter of residual disease at the end of cytoreductive surgery is one of the most important prognostic factors, chances to achieve complete debulking of tumor should be optimized. Therefore, cytoreductive surgery is best performed in an expert center. To establish such an expert center, not only surgical skills and experience are needed. High quality surgical care is delivered by a multidisciplinary team of, among others, oncology nurses, anesthesiologists, pathologists, dieticians and physiotherapists. Furthermore, expert centers typically deliver ... Gynecologic Oncology journals http://www.medworm.com/rss/comments.php?id=2603357 Thu, 16 Jul 2009 08:56:28 +0100 2603357 http://www.medworm.com/index.php?rid=2603356&cid=s_35590_6_f&fid=35590&url=http%3A%2F%2Fwww.ncbi.nlm.nih.gov%2Fentrez%2Fquery.fcgi%3Ftmpl%3DNoSidebarfile%26db%3DPubMed%26cmd%3DRetrieve%26list_uids%3D19573700%26dopt%3DAbstract Authors: Crandon AJ, Obermair A The thoroughness of cytoreductive surgery is the largest contributor to survival for patients with advanced ovarian and primary peritoneal carcinoma. For many years the surgery undertaken by Gynaecologic Oncologists has been tailored to match their surgical training. Future surgical training of Gynaecologic Oncologists needs to be tailored to the surgery required to provide complete tumour removal to no residual disease. This means the better teaching of anatomy and an increased scope of surgery to include the general and upper abdominal procedures and management required. This paradigm shift will be a challenge for all and impossible for some. It will require a significant mind-shift not only from our craft group and the profession at large but especial... Gynecologic Oncology journals http://www.medworm.com/rss/comments.php?id=2603356 Thu, 16 Jul 2009 08:56:26 +0100 2603356 http://www.medworm.com/index.php?rid=2603355&cid=s_35590_6_f&fid=35590&url=http%3A%2F%2Fwww.ncbi.nlm.nih.gov%2Fentrez%2Fquery.fcgi%3Ftmpl%3DNoSidebarfile%26db%3DPubMed%26cmd%3DRetrieve%26list_uids%3D19573701%26dopt%3DAbstract Authors: Magrina JF PMID: 19573701 [PubMed - indexed for MEDLINE] (Source: Gynecologic Oncology) Gynecologic Oncology journals http://www.medworm.com/rss/comments.php?id=2603355 Thu, 16 Jul 2009 08:56:24 +0100 2603355 http://www.medworm.com/index.php?rid=2603354&cid=s_35590_6_f&fid=35590&url=http%3A%2F%2Fwww.ncbi.nlm.nih.gov%2Fentrez%2Fquery.fcgi%3Ftmpl%3DNoSidebarfile%26db%3DPubMed%26cmd%3DRetrieve%26list_uids%3D19573702%26dopt%3DAbstract CONCLUSIONS: Robotic surgery is gaining acceptance and is rapidly growing as evidenced by an increased number of publications on the topic; these publications demonstrate the safety, efficacy, and improved outcomes compared to open surgery and conventional laparoscopy. PMID: 19573702 [PubMed - indexed for MEDLINE] (Source: Gynecologic Oncology) Gynecologic Oncology journals http://www.medworm.com/rss/comments.php?id=2603354 Thu, 16 Jul 2009 08:56:20 +0100 2603354 http://www.medworm.com/index.php?rid=2603353&cid=s_35590_6_f&fid=35590&url=http%3A%2F%2Fwww.ncbi.nlm.nih.gov%2Fentrez%2Fquery.fcgi%3Ftmpl%3DNoSidebarfile%26db%3DPubMed%26cmd%3DRetrieve%26list_uids%3D19573703%26dopt%3DAbstract This article will focus on the role and program development of advanced cytoreductive surgery in patients with gynecologic peritoneal malignancies. This review is an attempt to provide guidance for the rationale and strategic approach to develop the surgical skill set, meet institutional requirements, and implement the concept of a comprehensive cytoreductive surgical team. PMID: 19573703 [PubMed - indexed for MEDLINE] (Source: Gynecologic Oncology) Gynecologic Oncology journals http://www.medworm.com/rss/comments.php?id=2603353 Thu, 16 Jul 2009 08:56:18 +0100 2603353 http://www.medworm.com/index.php?rid=2603352&cid=s_35590_6_f&fid=35590&url=http%3A%2F%2Fwww.ncbi.nlm.nih.gov%2Fentrez%2Fquery.fcgi%3Ftmpl%3DNoSidebarfile%26db%3DPubMed%26cmd%3DRetrieve%26list_uids%3D19573704%26dopt%3DAbstract Authors: Leblanc E, Narducci F, Ferron G, Querleu D Young women affected by a malignant tumor have to cope, after the announcement of diagnosis, with the treatment and its secondary effects. Indeed, some of them may definitively impact on their fertility potential. Especially in pelvic tumors, treatments are more or less mutilating, either by a direct surgical resection of pelvic organs or by destruction of their functioning after chemotherapy or radiation therapy. Surgeons are often at the front line in the management of gynecologic tumors. It is important for them to be aware not only of the surgical techniques currently available to preserve fertility, but as well of their indications and limits, according to the tumor type or its treatment. This knowledge will enable them to delive... Gynecologic Oncology journals http://www.medworm.com/rss/comments.php?id=2603352 Thu, 16 Jul 2009 08:56:15 +0100 2603352 http://www.medworm.com/index.php?rid=2603351&cid=s_35590_6_f&fid=35590&url=http%3A%2F%2Fwww.ncbi.nlm.nih.gov%2Fentrez%2Fquery.fcgi%3Ftmpl%3DNoSidebarfile%26db%3DPubMed%26cmd%3DRetrieve%26list_uids%3D19573705%26dopt%3DAbstract Authors: Liang Z, Chen G, Xu H, Chen Y, Wang D Laparoscopic surgery for gynecological oncology is an important progress in the combination of scientific, technological and surgical techniques, which not only enhanced the efficacy of surgical treatment of gynecological oncology, but also is superior to conventional open surgery with regard to postoperative mental rehabilitation in gynecological oncology patients. But it is not without its risks and complications. There are still several new challenges on both theory and surgical skill improvement to be overcome. Firstly, to form a laparoscopic surgical team, there are a lot of special requirements of both the team members and the equipment which restrict the popularization of the laparoscopic radical hysterectomy. Secondly, every detail... Gynecologic Oncology journals http://www.medworm.com/rss/comments.php?id=2603351 Thu, 16 Jul 2009 08:56:12 +0100 2603351 http://www.medworm.com/index.php?rid=2603350&cid=s_35590_6_f&fid=35590&url=http%3A%2F%2Fwww.ncbi.nlm.nih.gov%2Fentrez%2Fquery.fcgi%3Ftmpl%3DNoSidebarfile%26db%3DPubMed%26cmd%3DRetrieve%26list_uids%3D19573706%26dopt%3DAbstract Authors: Goff BA PMID: 19573706 [PubMed - indexed for MEDLINE] (Source: Gynecologic Oncology) Gynecologic Oncology journals http://www.medworm.com/rss/comments.php?id=2603350 Thu, 16 Jul 2009 08:56:09 +0100 2603350 http://www.medworm.com/index.php?rid=2603349&cid=s_35590_6_f&fid=35590&url=http%3A%2F%2Fwww.ncbi.nlm.nih.gov%2Fentrez%2Fquery.fcgi%3Ftmpl%3DNoSidebarfile%26db%3DPubMed%26cmd%3DRetrieve%26list_uids%3D19573707%26dopt%3DAbstract Authors: Hoffman MS, Bodurka DC The purpose of this paper is to provide information about gynecologic oncology fellowship training and guidance in program development. The characteristics necessary for a physician to develop into a successful gynecologic oncologist include an extensive fund of knowledge related to the subspecialty, strong interpersonal skills, the ability to practice within the complex systems required for management of gynecologic cancer patients, surgical expertise, and the clinical ability to provide comprehensive oncologic care for these women. In order for a trainee to acquire these skills, a gynecologic oncology training program must accept only highly qualified individuals as fellows, have a dedicated core faculty, practice in a supportive environment that has a... Gynecologic Oncology journals http://www.medworm.com/rss/comments.php?id=2603349 Thu, 16 Jul 2009 08:56:07 +0100 2603349 http://www.medworm.com/index.php?rid=2603348&cid=s_35590_6_f&fid=35590&url=http%3A%2F%2Fwww.ncbi.nlm.nih.gov%2Fentrez%2Fquery.fcgi%3Ftmpl%3DNoSidebarfile%26db%3DPubMed%26cmd%3DRetrieve%26list_uids%3D19573708%26dopt%3DAbstract Authors: Cibula D, Kesic V Post-graduate training in oncogynecological surgery should be based on a comprehensive system with three main components: training centers, trainers and trainees. For each of these components, clearly defined requirements should be established. An international consensus on classification, terminology, and performance of standard procedures in gynecological oncology would further improve postgraduate training. One of the key features of this system should be continuous assessment of surgical and non-surgical skills that would make possible the evaluation of individual trainees' progress, as well as the quality of training centers and trainers. Special attention should be paid to the development of tailored educational tools. Internet databases of video presen... Gynecologic Oncology journals http://www.medworm.com/rss/comments.php?id=2603348 Thu, 16 Jul 2009 08:56:04 +0100 2603348 http://www.medworm.com/index.php?rid=2573794&cid=s_35590_6_f&fid=35590&url=http%3A%2F%2Fwww.ncbi.nlm.nih.gov%2Fentrez%2Fquery.fcgi%3Ftmpl%3DNoSidebarfile%26db%3DPubMed%26cmd%3DRetrieve%26list_uids%3D19572417%26dopt%3DAbstract DISCUSSION: Our current specimen collections are inadequate for discovery and validation of biomarkers. Current and future trials should mandate collection of fixed tissues as well as DNA/RNA. Effective crossgroup collaboration is necessary to permit timely completion of phase III trials. Centers with appropriate expertise and resources in the developing world should be encouraged to participate in the current clinical trial networks. PMID: 19572417 [PubMed - in process] (Source: Gynecologic Oncology) Gynecologic Oncology journals http://www.medworm.com/rss/comments.php?id=2573794 Tue, 07 Jul 2009 03:46:05 +0100 2573794 http://www.medworm.com/index.php?rid=2557700&cid=s_35590_6_f&fid=35590&url=http%3A%2F%2Fwww.ncbi.nlm.nih.gov%2Fentrez%2Fquery.fcgi%3Ftmpl%3DNoSidebarfile%26db%3DPubMed%26cmd%3DRetrieve%26list_uids%3D19559942%26dopt%3DAbstract Authors: Ramirez PT PMID: 19559942 [PubMed - in process] (Source: Gynecologic Oncology) Gynecologic Oncology journals http://www.medworm.com/rss/comments.php?id=2557700 Wed, 01 Jul 2009 15:10:05 +0100 2557700 http://www.medworm.com/index.php?rid=2530097&cid=s_35590_6_f&fid=35590&url=http%3A%2F%2Fwww.ncbi.nlm.nih.gov%2Fsites%2Fentrez%3Fcmd%3DSearch%26db%3Dpubmed%26term%3D%28%2520%28%2522Gynecol%2520Oncol%2522%255Bta%255D%29%2520AND%2520%25222009%252F04%252F06%252023.31%2522%255BEDAT%255D%253A%25222009%252F06%252F27%252010.03%2522%255BEDAT%255D%29 114 new pubmed citations were retrieved for your search. Click on the search hyperlink below to display the complete search results: "Gynecol Oncol"[ta] These pubmed results were generated on 2009/06/27PubMed, a service of the National Library of Medicine, includes over 15 million citations for biomedical articles back to the 1950's. These citations are from MEDLINE and additional life science journals. PubMed includes links to many sites providing full text articles and other related resources. (Source: Gynecologic Oncology) Gynecologic Oncology journals http://www.medworm.com/rss/comments.php?id=2530097 Sat, 27 Jun 2009 14:03:14 +0100 2530097 http://www.medworm.com/index.php?rid=2304382&cid=s_35590_6_f&fid=35590&url=http%3A%2F%2Fwww.ncbi.nlm.nih.gov%2Fentrez%2Fquery.fcgi%3Ftmpl%3DNoSidebarfile%26db%3DPubMed%26cmd%3DRetrieve%26list_uids%3D19309637%26dopt%3DAbstract Authors: Monk BJ, Ali S, Gaffney DK PMID: 19309637 [PubMed - indexed for MEDLINE] (Source: Gynecologic Oncology) Gynecologic Oncology journals http://www.medworm.com/rss/comments.php?id=2304382 Wed, 01 Apr 2009 04:00:00 +0100 2304382 http://www.medworm.com/index.php?rid=2304381&cid=s_35590_6_f&fid=35590&url=http%3A%2F%2Fwww.ncbi.nlm.nih.gov%2Fentrez%2Fquery.fcgi%3Ftmpl%3DNoSidebarfile%26db%3DPubMed%26cmd%3DRetrieve%26list_uids%3D19309638%26dopt%3DAbstract Authors: PMID: 19309638 [PubMed - indexed for MEDLINE] (Source: Gynecologic Oncology) Gynecologic Oncology journals http://www.medworm.com/rss/comments.php?id=2304381 Wed, 01 Apr 2009 04:00:00 +0100 2304381 http://www.medworm.com/index.php?rid=2304378&cid=s_35590_6_f&fid=35590&url=http%3A%2F%2Fwww.ncbi.nlm.nih.gov%2Fentrez%2Fquery.fcgi%3Ftmpl%3DNoSidebarfile%26db%3DPubMed%26cmd%3DRetrieve%26list_uids%3D19342083%26dopt%3DAbstract CONCLUSION: Our results suggest that in this cohort of patients with uterine STUMP the recurrence rate was 7%. Recurrences can be in the form of STUMP or leiomyosarcoma. PMID: 19342083 [PubMed - as supplied by publisher] (Source: Gynecologic Oncology) Gynecologic Oncology journals http://www.medworm.com/rss/comments.php?id=2304378 Tue, 31 Mar 2009 04:00:00 +0100 2304378 http://www.medworm.com/index.php?rid=2304380&cid=s_35590_6_f&fid=35590&url=http%3A%2F%2Fwww.ncbi.nlm.nih.gov%2Fentrez%2Fquery.fcgi%3Ftmpl%3DNoSidebarfile%26db%3DPubMed%26cmd%3DRetrieve%26list_uids%3D19321194%26dopt%3DAbstract CONCLUSION: Both resveratrol and EGCG induced significant reductions in the amount of VEGF secreted into the supernatant of cultured endometrial cancer cells. These results suggest that resveratrol and EGCG may have the potential to inhibit angiogenesis in endometrial tumours. Further investigation of these substances in endometrial cancer is warranted. PMID: 19321194 [PubMed - as supplied by publisher] (Source: Gynecologic Oncology) Gynecologic Oncology journals http://www.medworm.com/rss/comments.php?id=2304380 Mon, 23 Mar 2009 04:00:00 +0100 2304380 http://www.medworm.com/index.php?rid=2304379&cid=s_35590_6_f&fid=35590&url=http%3A%2F%2Fwww.ncbi.nlm.nih.gov%2Fentrez%2Fquery.fcgi%3Ftmpl%3DNoSidebarfile%26db%3DPubMed%26cmd%3DRetrieve%26list_uids%3D19321195%26dopt%3DAbstract CONCLUSIONS: Our findings suggest that the up-regulation of E-cadherin is an early defining event in ovarian cancer and may play a significant role in the initial development of the primary ovarian tumor. E-cadherin also appears to be important in the development of secondary tumors within the peritoneal cavity. Our data suggest that E-cadherin may prove to be an important target in the preventative treatment of metastatic ovarian cancer and further confirm that the laying hen is a good model for the study of human epithelial ovarian carcinoma. PMID: 19321195 [PubMed - as supplied by publisher] (Source: Gynecologic Oncology) Gynecologic Oncology journals http://www.medworm.com/rss/comments.php?id=2304379 Mon, 23 Mar 2009 04:00:00 +0100 2304379 http://www.medworm.com/index.php?rid=2304383&cid=s_35590_6_f&fid=35590&url=http%3A%2F%2Fwww.ncbi.nlm.nih.gov%2Fentrez%2Fquery.fcgi%3Ftmpl%3DNoSidebarfile%26db%3DPubMed%26cmd%3DRetrieve%26list_uids%3D19307014%26dopt%3DAbstract CONCLUSION: The combination of weekly topotecan and docetaxel has clinical benefit and is well tolerated in this heavily treated patient population. Patients with platinum-resistant tumors had clinical benefit and should be considered for further study with this regimen. PMID: 19307014 [PubMed - as supplied by publisher] (Source: Gynecologic Oncology) Gynecologic Oncology journals http://www.medworm.com/rss/comments.php?id=2304383 Sat, 21 Mar 2009 04:00:00 +0100 2304383 http://www.medworm.com/index.php?rid=2286563&cid=s_35590_6_f&fid=35590&url=http%3A%2F%2Fwww.ncbi.nlm.nih.gov%2Fentrez%2Fquery.fcgi%3Ftmpl%3DNoSidebarfile%26db%3DPubMed%26cmd%3DRetrieve%26list_uids%3D19297012%26dopt%3DAbstract CONCLUSION: The clinical features and treatment of EGIST are not well known because few cases have been reported. Pathologically, immunohistochemistry with antibody against c-kit protein (CD117) is valuable for diagnosis of EGIST. Mitotic rate is the most reliable prognostic factor, and mutations in KIT may be a clinically useful adjunct marker in the evaluation. Surgery is the most effective treatment, and long-term follow-up is necessary. PMID: 19297012 [PubMed - as supplied by publisher] (Source: Gynecologic Oncology) Gynecologic Oncology journals http://www.medworm.com/rss/comments.php?id=2286563 Mon, 16 Mar 2009 04:00:00 +0100 2286563 http://www.medworm.com/index.php?rid=2286562&cid=s_35590_6_f&fid=35590&url=http%3A%2F%2Fwww.ncbi.nlm.nih.gov%2Fentrez%2Fquery.fcgi%3Ftmpl%3DNoSidebarfile%26db%3DPubMed%26cmd%3DRetrieve%26list_uids%3D19297013%26dopt%3DAbstract CONCLUSIONS: Patients who underwent the SLN-procedure report less treatment related morbidity compared to those who underwent inguinofemoral lymphadenectomy. However, this did not influence overall quality of life. Furthermore, patients who underwent inguinofemoral lymphadenectomy are more reserved in advising the SLN-procedure to relatives. PMID: 19297013 [PubMed - as supplied by publisher] (Source: Gynecologic Oncology) Gynecologic Oncology journals http://www.medworm.com/rss/comments.php?id=2286562 Mon, 16 Mar 2009 04:00:00 +0100 2286562 http://www.medworm.com/index.php?rid=2286561&cid=s_35590_6_f&fid=35590&url=http%3A%2F%2Fwww.ncbi.nlm.nih.gov%2Fentrez%2Fquery.fcgi%3Ftmpl%3DNoSidebarfile%26db%3DPubMed%26cmd%3DRetrieve%26list_uids%3D19297014%26dopt%3DAbstract CONCLUSIONS: Compliance to the Dutch national routine follow-up protocol in HSIL patients after LLETZ is only moderate. For HSIL patients with free excision margins after LLETZ the first cytological follow-up interval can safely be increased to 12 months. PMID: 19297014 [PubMed - as supplied by publisher] (Source: Gynecologic Oncology) Gynecologic Oncology journals http://www.medworm.com/rss/comments.php?id=2286561 Mon, 16 Mar 2009 04:00:00 +0100 2286561 http://www.medworm.com/index.php?rid=2262483&cid=s_35590_6_f&fid=35590&url=http%3A%2F%2Fwww.ncbi.nlm.nih.gov%2Fentrez%2Fquery.fcgi%3Ftmpl%3DNoSidebarfile%26db%3DPubMed%26cmd%3DRetrieve%26list_uids%3D19282022%26dopt%3DAbstract CONCLUSION: The surgical anatomy knowledge of subspecialty trainees was weak but improved as a result of the dissection course. The most positive finding was the course evaluation. Postgraduate surgical training in GO would likely be enhanced by, and arguably requires, cadaveric dissection. "Soft-preserved" rather than formalin-fixed cadavers should be used. PMID: 19282022 [PubMed - as supplied by publisher] (Source: Gynecologic Oncology) Gynecologic Oncology journals http://www.medworm.com/rss/comments.php?id=2262483 Tue, 10 Mar 2009 04:00:00 +0100 2262483 http://www.medworm.com/index.php?rid=2262487&cid=s_35590_6_f&fid=35590&url=http%3A%2F%2Fwww.ncbi.nlm.nih.gov%2Fentrez%2Fquery.fcgi%3Ftmpl%3DNoSidebarfile%26db%3DPubMed%26cmd%3DRetrieve%26list_uids%3D19275957%26dopt%3DAbstract CONCLUSIONS: The diagnosis of mucinous invasive adenocarcinoma was difficult. Since patients with mucinous invasive adenocarcinoma had a lower response to chemotherapy, aggressive cytoreductive surgery was an effective treatment to improve the prognosis for advanced stage patients. A new chemotherapeutic regimen should be established for mucinous adenocarcinoma of the ovary. PMID: 19275957 [PubMed - as supplied by publisher] (Source: Gynecologic Oncology) Gynecologic Oncology journals http://www.medworm.com/rss/comments.php?id=2262487 Mon, 09 Mar 2009 04:00:00 +0100 2262487 http://www.medworm.com/index.php?rid=2262485&cid=s_35590_6_f&fid=35590&url=http%3A%2F%2Fwww.ncbi.nlm.nih.gov%2Fentrez%2Fquery.fcgi%3Ftmpl%3DNoSidebarfile%26db%3DPubMed%26cmd%3DRetrieve%26list_uids%3D19275958%26dopt%3DAbstract CONCLUSION: Although this study has its limitation due to the small sample size, it raises the question of the prognostic significance of MSI in high grade endometrial carcinoma. It also points to the importance of evaluating three mismatch repair genes (MLH1, MSH2, and MSH6) as a prognostic indicator. PMID: 19275958 [PubMed - as supplied by publisher] (Source: Gynecologic Oncology) Gynecologic Oncology journals http://www.medworm.com/rss/comments.php?id=2262485 Mon, 09 Mar 2009 04:00:00 +0100 2262485 http://www.medworm.com/index.php?rid=2262491&cid=s_35590_6_f&fid=35590&url=http%3A%2F%2Fwww.ncbi.nlm.nih.gov%2Fentrez%2Fquery.fcgi%3Ftmpl%3DNoSidebarfile%26db%3DPubMed%26cmd%3DRetrieve%26list_uids%3D19272638%26dopt%3DAbstract CONCLUSIONS: Since optimal treatment of uterine serous carcinoma remains unknown, novel therapeutic approaches need to be actively pursued. In the current study of primary USC tumors, oncogenic mutations of the PIK3CA gene were seen in 15% of USC cases. This represents the first report of this gene mutation in USC. In addition, EGFR stained positively in the majority of cases, suggesting a possible target protein. These findings warrant further investigation and suggest a potential role for therapeutic agents targeting the PI3K-AKT-mTOR pathway, such as rapamycin, as well as possible targets of EGFR in the treatment of uterine serous carcinoma. PMID: 19272638 [PubMed - as supplied by publisher] (Source: Gynecologic Oncology) Gynecologic Oncology journals http://www.medworm.com/rss/comments.php?id=2262491 Sat, 07 Mar 2009 05:00:00 +0100 2262491 http://www.medworm.com/index.php?rid=2262489&cid=s_35590_6_f&fid=35590&url=http%3A%2F%2Fwww.ncbi.nlm.nih.gov%2Fentrez%2Fquery.fcgi%3Ftmpl%3DNoSidebarfile%26db%3DPubMed%26cmd%3DRetrieve%26list_uids%3D19272639%26dopt%3DAbstract CONCLUSION(S): ERBB2 amplification is a rare event and has no predictive or prognostic value in suboptimally-resected, advanced stage EOC treated with platinum-based combination chemotherapy. PMID: 19272639 [PubMed - as supplied by publisher] (Source: Gynecologic Oncology) Gynecologic Oncology journals http://www.medworm.com/rss/comments.php?id=2262489 Sat, 07 Mar 2009 05:00:00 +0100 2262489 http://www.medworm.com/index.php?rid=2250966&cid=s_35590_6_f&fid=35590&url=http%3A%2F%2Fwww.ncbi.nlm.nih.gov%2Fentrez%2Fquery.fcgi%3Ftmpl%3DNoSidebarfile%26db%3DPubMed%26cmd%3DRetrieve%26list_uids%3D19269684%26dopt%3DAbstract CONCLUSION: In our experience, the revised FIGO/modified WHO scoring system has down scored some patients who would have been considered as high risk with the previous scoring system. A trend to lower CR with first line chemotherapy and an increase in the need for second line chemotherapy was seen. PMID: 19269684 [PubMed - as supplied by publisher] (Source: Gynecologic Oncology) Gynecologic Oncology journals http://www.medworm.com/rss/comments.php?id=2250966 Fri, 06 Mar 2009 05:00:00 +0100 2250966 http://www.medworm.com/index.php?rid=2250970&cid=s_35590_6_f&fid=35590&url=http%3A%2F%2Fwww.ncbi.nlm.nih.gov%2Fentrez%2Fquery.fcgi%3Ftmpl%3DNoSidebarfile%26db%3DPubMed%26cmd%3DRetrieve%26list_uids%3D19268342%26dopt%3DAbstract CONCLUSIONS: Carboplatin-paclitaxel is active and well tolerated in patients with recurrent cervical cancer after definitive radiotherapy. This combination should be considered as an alternative regimen to cisplatin-paclitaxel in this patient population. PMID: 19268342 [PubMed - as supplied by publisher] (Source: Gynecologic Oncology) Gynecologic Oncology journals http://www.medworm.com/rss/comments.php?id=2250970 Thu, 05 Mar 2009 05:00:00 +0100 2250970 http://www.medworm.com/index.php?rid=2250968&cid=s_35590_6_f&fid=35590&url=http%3A%2F%2Fwww.ncbi.nlm.nih.gov%2Fentrez%2Fquery.fcgi%3Ftmpl%3DNoSidebarfile%26db%3DPubMed%26cmd%3DRetrieve%26list_uids%3D19269022%26dopt%3DAbstract Authors: Tinelli R, Cicinelli E, Tinelli A, Malzoni M PMID: 19269022 [PubMed - as supplied by publisher] (Source: Gynecologic Oncology) Gynecologic Oncology journals http://www.medworm.com/rss/comments.php?id=2250968 Thu, 05 Mar 2009 05:00:00 +0100 2250968 http://www.medworm.com/index.php?rid=2250969&cid=s_35590_6_f&fid=35590&url=http%3A%2F%2Fwww.ncbi.nlm.nih.gov%2Fentrez%2Fquery.fcgi%3Ftmpl%3DNoSidebarfile%26db%3DPubMed%26cmd%3DRetrieve%26list_uids%3D19268343%26dopt%3DAbstract CONCLUSION: The lymph nodes count are higher when surgical nodes were sent as multiple separated instead of single specimens, regardless of the side of the pelvis. PMID: 19268343 [PubMed - as supplied by publisher] (Source: Gynecologic Oncology) Gynecologic Oncology journals http://www.medworm.com/rss/comments.php?id=2250969 Wed, 04 Mar 2009 05:00:00 +0100 2250969 http://www.medworm.com/index.php?rid=2249392&cid=s_35590_6_f&fid=35590&url=http%3A%2F%2Fwww.ncbi.nlm.nih.gov%2Fentrez%2Fquery.fcgi%3Ftmpl%3DNoSidebarfile%26db%3DPubMed%26cmd%3DRetrieve%26list_uids%3D19264351%26dopt%3DAbstract CONCLUSION: This pre and post-carboplatin cytokine regimen resulted in a reasonable response and a hematologic profile that could invite further evaluation of its components in the treatment of patients with ovarian cancer. PMID: 19264351 [PubMed - as supplied by publisher] (Source: Gynecologic Oncology) Gynecologic Oncology journals http://www.medworm.com/rss/comments.php?id=2249392 Tue, 03 Mar 2009 05:00:00 +0100 2249392 http://www.medworm.com/index.php?rid=2249391&cid=s_35590_6_f&fid=35590&url=http%3A%2F%2Fwww.ncbi.nlm.nih.gov%2Fentrez%2Fquery.fcgi%3Ftmpl%3DNoSidebarfile%26db%3DPubMed%26cmd%3DRetrieve%26list_uids%3D19264352%26dopt%3DAbstract CONCLUSION: Lymphatic mapping and SLN identification improved safety in less radical surgery in early stage cervical cancer. This preliminary study showed that it is both feasible and safe to reduce the radicality of parametrial resection for small tumor volume in SLN negative patients. Results also indicated that treatment-associated morbidity is low. PMID: 19264352 [PubMed - as supplied by publisher] (Source: Gynecologic Oncology) Gynecologic Oncology journals http://www.medworm.com/rss/comments.php?id=2249391 Tue, 03 Mar 2009 05:00:00 +0100 2249391 http://www.medworm.com/index.php?rid=2241288&cid=s_35590_6_f&fid=35590&url=http%3A%2F%2Fwww.ncbi.nlm.nih.gov%2Fentrez%2Fquery.fcgi%3Ftmpl%3DNoSidebarfile%26db%3DPubMed%26cmd%3DRetrieve%26list_uids%3D19261323%26dopt%3DAbstract CONCLUSIONS: In the case-control part of the study, we found that TN and CA125 deserve to be validated on pre-clinical samples by inclusion in future marker panels. The RAI is also a potential new candidate for a diagnostic tool for selecting patients at high risk for having OC; hence it deserves further evaluation in a prospective clinical study. PMID: 19261323 [PubMed - as supplied by publisher] (Source: Gynecologic Oncology) Gynecologic Oncology journals http://www.medworm.com/rss/comments.php?id=2241288 Mon, 02 Mar 2009 05:00:00 +0100 2241288 http://www.medworm.com/index.php?rid=2241287&cid=s_35590_6_f&fid=35590&url=http%3A%2F%2Fwww.ncbi.nlm.nih.gov%2Fentrez%2Fquery.fcgi%3Ftmpl%3DNoSidebarfile%26db%3DPubMed%26cmd%3DRetrieve%26list_uids%3D19263582%26dopt%3DAbstract CONCLUSION: ALCAR does not affect the cytotoxicity of paclitaxel or carboplatin. There was no increase in proliferation, or NGFR of OVCAR-3 or SKOV-3 cells exposed to ALCAR. PMID: 19263582 [PubMed - in process] (Source: Gynecologic Oncology) Gynecologic Oncology journals http://www.medworm.com/rss/comments.php?id=2241287 Sun, 01 Mar 2009 05:00:00 +0100 2241287 http://www.medworm.com/index.php?rid=2222851&cid=s_35590_6_f&fid=35590&url=http%3A%2F%2Fwww.ncbi.nlm.nih.gov%2Fentrez%2Fquery.fcgi%3Ftmpl%3DNoSidebarfile%26db%3DPubMed%26cmd%3DRetrieve%26list_uids%3D19245944%26dopt%3DAbstract Authors: Walker JL PMID: 19245944 [PubMed - in process] (Source: Gynecologic Oncology) Gynecologic Oncology journals http://www.medworm.com/rss/comments.php?id=2222851 Sun, 01 Mar 2009 01:27:15 +0100 2222851 http://www.medworm.com/index.php?rid=2222853&cid=s_35590_6_f&fid=35590&url=http%3A%2F%2Fwww.ncbi.nlm.nih.gov%2Fentrez%2Fquery.fcgi%3Ftmpl%3DNoSidebarfile%26db%3DPubMed%26cmd%3DRetrieve%26list_uids%3D19243813%26dopt%3DAbstract CONCLUSIONS: The prognostic influence of the proteasomal subunit MB1 and the MHC class I complex in ovarian cancer provides a rationale for targeting these specific APPP components in ovarian cancer. PMID: 19243813 [PubMed - as supplied by publisher] (Source: Gynecologic Oncology) Gynecologic Oncology journals http://www.medworm.com/rss/comments.php?id=2222853 Mon, 23 Feb 2009 05:00:00 +0100 2222853 http://www.medworm.com/index.php?rid=2222852&cid=s_35590_6_f&fid=35590&url=http%3A%2F%2Fwww.ncbi.nlm.nih.gov%2Fentrez%2Fquery.fcgi%3Ftmpl%3DNoSidebarfile%26db%3DPubMed%26cmd%3DRetrieve%26list_uids%3D19243814%26dopt%3DAbstract CONCLUSIONS: These preliminary results suggest that microlaparoscopy is a safe and adequate surgical option for endometrial cancer staging, with the potential to further decrease invasiveness of the conventional laparoscopic approach. PMID: 19243814 [PubMed - as supplied by publisher] (Source: Gynecologic Oncology) Gynecologic Oncology journals http://www.medworm.com/rss/comments.php?id=2222852 Mon, 23 Feb 2009 05:00:00 +0100 2222852 http://www.medworm.com/index.php?rid=2216929&cid=s_35590_6_f&fid=35590&url=http%3A%2F%2Fwww.ncbi.nlm.nih.gov%2Fentrez%2Fquery.fcgi%3Ftmpl%3DNoSidebarfile%26db%3DPubMed%26cmd%3DRetrieve%26list_uids%3D19239974%26dopt%3DAbstract Conclusions. Fulvestrant is well-tolerated and efficacious. Objective response rates are low, but disease stabilization was common. PMID: 19239974 [PubMed - as supplied by publisher] (Source: Gynecologic Oncology) Gynecologic Oncology journals http://www.medworm.com/rss/comments.php?id=2216929 Sun, 22 Feb 2009 05:00:00 +0100 2216929 http://www.medworm.com/index.php?rid=2216931&cid=s_35590_6_f&fid=35590&url=http%3A%2F%2Fwww.ncbi.nlm.nih.gov%2Fentrez%2Fquery.fcgi%3Ftmpl%3DNoSidebarfile%26db%3DPubMed%26cmd%3DRetrieve%26list_uids%3D19237187%26dopt%3DAbstract Authors: Folkins AK, Jarboe EA, Roh MH, Crum CP Pelvic serous carcinoma has traditionally been viewed as a rapidly evolving malignancy, due principally to its late stage at diagnosis and tendency for poor outcome, both in the endometrium and the upper genital tract. Recently, studies of women with BRCA1 or BRCA2 mutations (BRCA+) undergoing risk reducing salpingo-oophorectomy have highlighted the distal fallopian tube as a common (80%) site of tumor origin and additional studies of unselected women with pelvic serous carcinoma have demonstrated that serous tubal intraepithelial carcinoma may precede a significant percentage of these tumors. This review examines the serous carcinogenic spectrum in the fallopian tube, highlighting recent evidence that these tumors may follow a defined pr... Gynecologic Oncology journals http://www.medworm.com/rss/comments.php?id=2216931 Sat, 21 Feb 2009 05:00:00 +0100 2216931 http://www.medworm.com/index.php?rid=2216930&cid=s_35590_6_f&fid=35590&url=http%3A%2F%2Fwww.ncbi.nlm.nih.gov%2Fentrez%2Fquery.fcgi%3Ftmpl%3DNoSidebarfile%26db%3DPubMed%26cmd%3DRetrieve%26list_uids%3D19237188%26dopt%3DAbstract CONCLUSION: We have identified miRNAs and their predicted target mRNAs associated with ovarian cancer cell response to chemotherapeutic agents. Our strategy of integrating miRNA and mRNA data may aid in the characterization of important molecular pathways associated with OVCA chemo-response. PMID: 19237188 [PubMed - as supplied by publisher] (Source: Gynecologic Oncology) Gynecologic Oncology journals http://www.medworm.com/rss/comments.php?id=2216930 Sat, 21 Feb 2009 05:00:00 +0100 2216930 http://www.medworm.com/index.php?rid=2211168&cid=s_35590_6_f&fid=35590&url=http%3A%2F%2Fwww.ncbi.nlm.nih.gov%2Fentrez%2Fquery.fcgi%3Ftmpl%3DNoSidebarfile%26db%3DPubMed%26cmd%3DRetrieve%26list_uids%3D19232697%26dopt%3DAbstract CONCLUSIONS: Targeted treatment with mAbs in conjunction with cytotoxic chemotherapy has been an important research area during the last decade. This therapeutic approach holds promise for improved outcomes in patients with ovarian cancer. PMID: 19232697 [PubMed - as supplied by publisher] (Source: Gynecologic Oncology) Gynecologic Oncology journals http://www.medworm.com/rss/comments.php?id=2211168 Thu, 19 Feb 2009 05:00:00 +0100 2211168 http://www.medworm.com/index.php?rid=2211167&cid=s_35590_6_f&fid=35590&url=http%3A%2F%2Fwww.ncbi.nlm.nih.gov%2Fentrez%2Fquery.fcgi%3Ftmpl%3DNoSidebarfile%26db%3DPubMed%26cmd%3DRetrieve%26list_uids%3D19232698%26dopt%3DAbstract Authors: Perrone AM, Meriggiola MC, Pelusi G PMID: 19232698 [PubMed - as supplied by publisher] (Source: Gynecologic Oncology) Gynecologic Oncology journals http://www.medworm.com/rss/comments.php?id=2211167 Thu, 19 Feb 2009 05:00:00 +0100 2211167 http://www.medworm.com/index.php?rid=2211166&cid=s_35590_6_f&fid=35590&url=http%3A%2F%2Fwww.ncbi.nlm.nih.gov%2Fentrez%2Fquery.fcgi%3Ftmpl%3DNoSidebarfile%26db%3DPubMed%26cmd%3DRetrieve%26list_uids%3D19232699%26dopt%3DAbstract CONCLUSION: Sentinel lymph node mapping using a cervical injection with combined Tc and blue dye is feasible and accurate in patients with grade 1 endometrial cancer and may be a reasonable option for this select group of patients. Regional lymphadenectomy remains the gold standard in many practices, particularly for the approximately 15% of cases with failed SLN mapping. PMID: 19232699 [PubMed - as supplied by publisher] (Source: Gynecologic Oncology) Gynecologic Oncology journals http://www.medworm.com/rss/comments.php?id=2211166 Thu, 19 Feb 2009 05:00:00 +0100 2211166 http://www.medworm.com/index.php?rid=2211165&cid=s_35590_6_f&fid=35590&url=http%3A%2F%2Fwww.ncbi.nlm.nih.gov%2Fentrez%2Fquery.fcgi%3Ftmpl%3DNoSidebarfile%26db%3DPubMed%26cmd%3DRetrieve%26list_uids%3D19232700%26dopt%3DAbstract Authors: Moore DH As gynecologic surgeons garnered a better understanding of various clinical-pathological prognostic factors, there evolved a number of modifications in the surgical approach allowing for more individualized therapy with less morbidity, while still retaining the curative potential of the radical vulvectomy operation. The incorporation of radiation therapy and eventually chemotherapy in the primary treatment of vulva cancer also represents a slow evolution in clinical management. The addition of chemotherapy concurrent to radiation therapy for the treatment of vulvar carcinoma was heavily influenced by advances in the treatment of cervical cancer, and squamous cell carcinoma of the anal canal. On the basis of many good phase II studies but no randomized controlled trial... Gynecologic Oncology journals http://www.medworm.com/rss/comments.php?id=2211165 Thu, 19 Feb 2009 05:00:00 +0100 2211165 http://www.medworm.com/index.php?rid=2211164&cid=s_35590_6_f&fid=35590&url=http%3A%2F%2Fwww.ncbi.nlm.nih.gov%2Fentrez%2Fquery.fcgi%3Ftmpl%3DNoSidebarfile%26db%3DPubMed%26cmd%3DRetrieve%26list_uids%3D19232701%26dopt%3DAbstract CONCLUSION: Treatment and follow-up must be performed not only for the adenocarcinoma element but also for the choriocarcinoma element in patients presenting with endometrial carcinoma with choriocarcinomatous differentiation. PMID: 19232701 [PubMed - as supplied by publisher] (Source: Gynecologic Oncology) Gynecologic Oncology journals http://www.medworm.com/rss/comments.php?id=2211164 Thu, 19 Feb 2009 05:00:00 +0100 2211164 http://www.medworm.com/index.php?rid=2211169&cid=s_35590_6_f&fid=35590&url=http%3A%2F%2Fwww.ncbi.nlm.nih.gov%2Fentrez%2Fquery.fcgi%3Ftmpl%3DNoSidebarfile%26db%3DPubMed%26cmd%3DRetrieve%26list_uids%3D19232434%26dopt%3DAbstract CONCLUSION: In this phase II trial, the combination Cp-Tc-Ce induced a high rate of serious adverse and/or fatal events at standard dose and schedule. Cetuximab plus platinum-based combination chemotherapy should be further explored with caution in the future in advanced cervix cancer. PMID: 19232434 [PubMed - as supplied by publisher] (Source: Gynecologic Oncology) Gynecologic Oncology journals http://www.medworm.com/rss/comments.php?id=2211169 Sat, 14 Feb 2009 05:00:00 +0100 2211169 http://www.medworm.com/index.php?rid=2190926&cid=s_35590_6_f&fid=35590&url=http%3A%2F%2Fwww.ncbi.nlm.nih.gov%2Fentrez%2Fquery.fcgi%3Ftmpl%3DNoSidebarfile%26db%3DPubMed%26cmd%3DRetrieve%26list_uids%3D19217147%26dopt%3DAbstract DISCUSSION: Local recurrence rates remain low after surgery and adjuvant radiation therapy for stage II endometrial cancer using a combination of VB and EXT tailored to the surgical and pathologic features. VB alone resulted in fewer toxicities without an increased recurrence risk compared to the combination of EXT and VB, suggesting that VB without EXT is sufficient for patients with low-risk histopathologic features and comprehensive surgical staging with complete lymphadenectomy. PMID: 19217147 [PubMed - as supplied by publisher] (Source: Gynecologic Oncology) Gynecologic Oncology journals http://www.medworm.com/rss/comments.php?id=2190926 Wed, 11 Feb 2009 05:00:00 +0100 2190926 http://www.medworm.com/index.php?rid=2190925&cid=s_35590_6_f&fid=35590&url=http%3A%2F%2Fwww.ncbi.nlm.nih.gov%2Fentrez%2Fquery.fcgi%3Ftmpl%3DNoSidebarfile%26db%3DPubMed%26cmd%3DRetrieve%26list_uids%3D19217148%26dopt%3DAbstract CONCLUSIONS: This study establishes societal preferences for a number of health states related to screening, diagnosis and treatment of ovarian cancer that can be used for assessing the cost-effectiveness of different ovarian cancer screening and treatment regimens. PMID: 19217148 [PubMed - as supplied by publisher] (Source: Gynecologic Oncology) Gynecologic Oncology journals http://www.medworm.com/rss/comments.php?id=2190925 Wed, 11 Feb 2009 05:00:00 +0100 2190925 http://www.medworm.com/index.php?rid=2190924&cid=s_35590_6_f&fid=35590&url=http%3A%2F%2Fwww.ncbi.nlm.nih.gov%2Fentrez%2Fquery.fcgi%3Ftmpl%3DNoSidebarfile%26db%3DPubMed%26cmd%3DRetrieve%26list_uids%3D19217149%26dopt%3DAbstract CONCLUSIONS: Vaccination with the AS04-adjuvanted HPV-16/18 vaccine is predicted to provide long-term persistence for both HPV-16 and -18 antibodies, independent of the statistical model applied. Model predictions are based on conservative mathematical assumptions. Since the input of longer term data of up to 6.4 years showed an improved profile compared with that for data up to 5.5 years, the predictions of antibody persistence based on population means are conservative when predicting that antibody levels will remain well above levels induced by natural infection for 20 years. PMID: 19217149 [PubMed - as supplied by publisher] (Source: Gynecologic Oncology) Gynecologic Oncology journals http://www.medworm.com/rss/comments.php?id=2190924 Wed, 11 Feb 2009 05:00:00 +0100 2190924 http://www.medworm.com/index.php?rid=2182928&cid=s_35590_6_f&fid=35590&url=http%3A%2F%2Fwww.ncbi.nlm.nih.gov%2Fentrez%2Fquery.fcgi%3Ftmpl%3DNoSidebarfile%26db%3DPubMed%26cmd%3DRetrieve%26list_uids%3D19211137%26dopt%3DAbstract CONCLUSION: Treatment of cAMP, through activation of PR-B, induced senescence and suppressed tumorigenicity in ovarian cancer cells. PMID: 19211137 [PubMed - as supplied by publisher] (Source: Gynecologic Oncology) Gynecologic Oncology journals http://www.medworm.com/rss/comments.php?id=2182928 Mon, 09 Feb 2009 05:00:00 +0100 2182928 http://www.medworm.com/index.php?rid=2177653&cid=s_35590_6_f&fid=35590&url=http%3A%2F%2Fwww.ncbi.nlm.nih.gov%2Fentrez%2Fquery.fcgi%3Ftmpl%3DNoSidebarfile%26db%3DPubMed%26cmd%3DRetrieve%26list_uids%3D19203783%26dopt%3DAbstract CONCLUSION: Genetic polymorphisms such as ERCC1 8092C>A, ABCB1 2677G>T/A, GSTP1 I105V and GSTT1 polymorphisms may affect drug response, toxicity and survival in patient with EOC who received taxane- and platinum-based chemotherapy after surgery. However, large-scale, prospective clinical studies are required for evaluating the role of genetic polymorphisms. PMID: 19203783 [PubMed - as supplied by publisher] (Source: Gynecologic Oncology) Gynecologic Oncology journals http://www.medworm.com/rss/comments.php?id=2177653 Sat, 07 Feb 2009 05:00:00 +0100 2177653 http://www.medworm.com/index.php?rid=2173266&cid=s_35590_6_f&fid=35590&url=http%3A%2F%2Fwww.ncbi.nlm.nih.gov%2Fentrez%2Fquery.fcgi%3Ftmpl%3DNoSidebarfile%26db%3DPubMed%26cmd%3DRetrieve%26list_uids%3D19201457%26dopt%3DAbstract CONCLUSIONS: With supportive measures, such as scheduled hydration and granulocyte colony-stimulating factors, outpatient administration of IP chemotherapy was feasible. This regimen resulted in few hospitalizations or treatment delays and demonstrated less toxicity than previously reported IP chemotherapy regimens. Port-related complications were a leading cause of IP chemotherapy discontinuation. PMID: 19201457 [PubMed - as supplied by publisher] (Source: Gynecologic Oncology) Gynecologic Oncology journals http://www.medworm.com/rss/comments.php?id=2173266 Fri, 06 Feb 2009 05:00:00 +0100 2173266 http://www.medworm.com/index.php?rid=2167864&cid=s_35590_6_f&fid=35590&url=http%3A%2F%2Fwww.ncbi.nlm.nih.gov%2Fentrez%2Fquery.fcgi%3Ftmpl%3DNoSidebarfile%26db%3DPubMed%26cmd%3DRetrieve%26list_uids%3D19193428%26dopt%3DAbstract CONCLUSIONS: We were unable to show that groin failure after superficial lymphadenectomy was a result of low lymph node count. The small number of recurrences made firm conclusions impossible. Variations in anatomy and other factors may make node counting an unreliable measure of surgical quality. PMID: 19193428 [PubMed - as supplied by publisher] (Source: Gynecologic Oncology) Gynecologic Oncology journals http://www.medworm.com/rss/comments.php?id=2167864 Mon, 02 Feb 2009 05:00:00 +0100 2167864